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1. Abbreviations
ACRO Somatotroph adenoma
ACTH Adrenocorticotroph hormone
ADH Antidiuretic hormone
BER Base excision repair
BRG1 Brahma related gene 1
CDKN2A Cyclin dependent kinase inhibitor 2A
COCl2 Cobalt-II-chloride
CREB c-AMP response binding element
CRH Corticotropin-releasing-hormone
DMEM Dulbecco’s modified Eagle Medium
DMSO Dimethyl sulfoxide
DNA Desoxyribonucleic acid
ECL Enhanced chemiluminescence
EDTA Ethylenediaminetetraacetic acid
EGF Epidermal growth factor
EGF-R Epidermal growth factor receptor
ELISA Enzyme linked immunosorbent assay
EMA European Medicines Agency
FDA U.S. Food and Drug Administration
FCS Fetal calf serum
FGF-2 Fibroblast growth factor 2
FGF-4 Fibroblast growth factor 4
FGFR4 Fibroblast growth factor receptor 4
FSH Follicle-stimulating hormone
fT3 Free triiodothyronine
fT4 Free thyroxine
GADD45 Growth arrest and DNA damage gene 45
GH Growth hormone
GHRH Growth hormone releasing hormone
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1. Abbreviations
GnRH Gonadotropin releasing hormone
GSα G-protein subunit α
Hif-1α Hypoxia inducible factor 1α
HMGA2 High mobility group AT-hook 2
HRP Horseradish peroxidase
IGF-1 Insulin like growth factor 1
KIP1 Kinesin like protein 1
LH Luteinizing hormone
MEG3 Maternally expressed gene 3
MGMT Methyl guanine methyl transferase
MRI Magnetic resonance imaging
MSH6 Mutator S homolog 6
MSH2 Mutator S homolog 2
MTIC Monomethyl triazenoimidazole carboxamide
NFPA Non-functioning pituitary adenoma
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PRL Prolactin
PTAG Pituitary tumor apoptosis gene
PTTG Pituitary tumor transforming gene
ras Rat sarcoma protein
Rb Retinoblastoma
RIA Radioimmunoassay
RIPA Radioimmunoprecipitation assay
rpm revolutions per minute
SDS Sodium Dodecyl Sulfate
T3 Triiodothyronine
T4 Thyroxine
TEMED Tetramethylethylenediamine
TGF-alpha Transforming growth factor
TMZ Temozolomide
Tp53 Tumor protein p53
TRH Thyrotropin-releasing-hormone
Tris Tris(hydroxymethyl)aminomethane
TSH Thyroid-stimulating hormone
VEGF Vascular endothelial growth factor
2
WST-1 Water soluble tetrazolium 1
ZAC Zink activated channel
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2. Background
2.1. The Pituitary Gland
2.1.1. Physiology of the Pituitary
The pituitary is a pea sized endocrine gland which is located in the sella turcica, a
small cavity in the base of the scull. It produces a variety of hormones that act as key
regulators for several important physiological functions. The secretion is regulated by the
hypothalamus to which the pituitary is connected through the pituitary stalk. The gland
is divided into two major parts: the anterior lobe and the posterior lobe. The anterior
lobe is regulated by different hypothalamic hormones such as CRH, TRH, GHRH and
GnRH, which reach the gland via a system of portal vessels. These hormones prompt
the pituitary gland to secrete the respective hormones ACTH, TSH, GH, PRL, LH and
FSH. TSH regulates the hormone secretion of the thyroid gland and ACTH stimulates
the adrenal glands to produce steroids. GH acts as a universal growth factor in the total
body, mainly through the production of insulin like growth factor 1 in the liver. PRL,
LH and FSH regulate reproduction in both males and females. Figure 2.1 highlights the
regulation of the anterior pituitary hormone secretion and the effects of the respective
hormones. The posterior lobe, the neurohypophysis, stores and releases the hormones
oxytocin and antidiuretic hormone. These two neuropeptides are synthesized by neurons
in the hypothalamus and transported to the posterior lobe along their axons [1]. Upon
stimulation by action potentials, the hormone-containing varicosities in the posterior
lobe release their content via exocytosis [2]. Oxytocin plays a role in social behavior and
it facilitates parturition and milk ejection in women [3]. Antidiuretic hormone leads to
vasoconstriction and retention of water in the kidney. Additionally it is also enforcing
the effect of CRH on corticotroph anterior pituitary cells [1]. In addition to the two
major lobes, the pituitary gland also contains the rudimentary intermediate lobe, whose
function in humans has not yet been completely understood [4].
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Figure 2.1. Physiologic functions of the pituitary gland.
Figure modified after [5]. Stimulation by the hypothalamic hormone CRH leads to secretion of ACTH,
which stimulates the adrenal glands to produce cortisol, which in turn inhibits further CRH and ACTH
release and plays an important role in regulating among other things the immunosystem, electrolyte
balance and glucose metabolism. The hypothalamic hormone TRH stimulates the pituitary gland
to secrete TSH, which promotes the secretion of T3 and T4 in the thyroid gland. T3 and T4 both
regulate metabolism and cell growth and inhibit TRH and TSH secretion in a negative feedback
mechanism. The hypothalamic hormone GHRH leads to pituitary secretion of GH. GH stimulates
growth and IGF-1 production. High IGF-1 levels reduce GH and GHRH production as a negative
feedback. PRL secretion is constantly inhibited by dopamine secretion and regulates lactation in
women. The hypothalamic hormone GnRH stimulates LH and FSH secretion of the pituitary gland,
which modulate the function of ovaries and testes.
2.1.2. Tumors of the Anterior Pituitary
Pituitary tumors account for approximately 13% of all brain tumors [8]. The prevalence
of pituitary tumors, determined by both radiographic and autopsy studies, has been
estimated to be 16.7% [9]. Data from the Swedish cancer registry suggest that the
incidence of pituitary neoplasms has increased over an observation period of 33 years
[10]. Typically, pituitary adenomas are benign tumors that don’t metastasize and that
may even be silent and detected only incidentally. However, there are some tumors
that can lead to death through hormonal excess and there are some that demonstrate
local aggressive behavior. The following sections will give an overview of these different
tumors.
2.1.2.1. Tumorigenesis
Currently, there are two conflicting theories about the underlying mechanisms of patho-
genesis of pituitary tumors. The hypothalamic hypothesis attributes tumor develop-
ment to a prolonged stimulation by hypothalamic hormones or respectively the loss of
hypothalamic inhibition on pituitary cells. This hypothesis is strengthened by the fact
that hypothalamic hormones have been shown to enhance pituitary cell growth and to
cause hyperplasia in animal models [11, 12]. However, it was shown that the tissue sur-
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rounding the tumors is free of hyperplasia. Furthermore, recurrence rates after complete
tumor removal are low [13]. These two observations seem to contradict the hypothalamic
hypothesis. The second hypothesis for pituitary tumorigenesis suggests that adenomas
derive from a single mutated cell, independent of hypothalamic stimulation. Monoclon-
ality has already been demonstrated in a large number of pituitary adenomas by gene
expression analyses [14, 15]. If hypothalamic stimulation was the cause for tumor devel-
opment, one would expect the tumor to be polyclonal since the stimulation affects the
entire gland. Besides that, mutations in genes like p53, Rb or Ras that are commonly
found in other cancer types occur rarely in pituitary adenomas [16, 17, 18]. Hence, the
details of tumorigenesis remain to be unvealed and other studies suggest a mechanism
such as a multistep-wise progression where genetic alterations arise more likely in a fertile
environment [19].
Oncogenes Tumor suppressor
genes
CREB GADD45
Cyclin D1 Menin
EGF/TGF-
alpha/EGF-R
p16/CDKN2A
FGF-2, FGF-4 p18
GSα p27/KIP1
PTTG Rb
FGFR4 Tp53
ras MEG3
HMGA2 BRG1
ZAC
DAP kinase
PTAG
Table 2.1. Factors involved in pituitary tu-
morigenesis.
Table modified after [6, 7] Listing is not exhaustive.
The occurrence of certain allelic dele-
tions and genetic mutations in pituitary
cells contributes to tumorigenesis. Al-
lelic deletions have been shown to corre-
late with tumor invasiveness. 75% of the
deletions are seen in 1p, 10q, 11q13 and
13q12–14 [20]. Overexpressed oncogenes
and silenced tumor suppressor genes asso-
ciated with pituitary tumors are shown in
table 2.1. The Pituitary tumor transform-
ing gene (PTTG) is one of these factors
and seems to play an important role in
tumorigenesis. It was found to be overex-
pressed in pituitary tumors compared to
normal pituitary tissue and it has been
shown to correlate with invasiveness [21].
2.1.2.2. Subtypes of Pituitary Tumors
Pituitary adenomas can be classified into
different subtypes according to their endocrine activity or immunohistochemical proper-
ties [22]. The prevalence of the adenoma subtypes as classified by immunohistochemistry
was studied in a large series of post mortem pituitaries by Buurman et al. They found
prolactinomas in 39,5% of pituitary adenomas, corticotroph adenomas in 13,8%, go-
nadotroph adenomas in 6,6%, somatotroph adenomas in 2% and thyrotroph adenomas
6
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in 0,6%. 22,5% were non-functioning adenomas, which do not stain for pituitary hor-
mones [23]. In addition to that, many adenomas that secrete more than one hormone
were reported. Most of them co-secrete growth hormone and prolactin. Anyway, when
elevated prolactin levels are found, it does not always have to be due to a prolactin
producing tumor. Instead, hyperprolactinemia is frequently found in patients with large
pituitary adenomas. Compression of the pituitary stalk by large adenomas prevents the
hypothalamus from inhibiting prolactin production, therefore leading to moderately el-
evated blood levels of prolactin. This phenomenon is called the “stalk effect”. Recent
research indicates that there must even be other factors than the “stalk effect” that in-
fluence the elevated prolactin levels in large non-prolactinomas. For example lactotroph
stimulating factors that have not yet been identified are supposed to be secreted by
tumors deriving from the “pars tuberalis” and mimick a “stalk effect” [24, 25].
Next to the specific effects of hormone secretion, all pituitary tumors have so called
“mass effects” due to their size: The obstruction of blood flow to the pituitary gland often
leads to hypopituitarism, which is observed in approximately 48% [26]. Besides that,
pituitary neoplasms can cause considerable complications through the compression of
the optic chiasm, which causes bilateral hemianopsia. An increase in intrasellar pressure
and stretching of the meninges can furthermore lead to headaches [26]. The adenomas
that cause these mass effects are usually greater than 10mm in diameter and referred
to as macroadenomas while smaller ones are named microadenomas.
In addition to the majority of the sporadic forms of adenomas, pituitary adenomas
can also originate from genetic syndromes such as multiple endocrine neoplasia type 1
(MEN1), Mc Cune Albright Syndrome, Familial isolated pituitary adenomas and Carney
complex [27].
Somatotroph Adenomas
Somatotroph adenomas are characterized by excessive secretion of growth hormone,
which leads to the typical clinical picture of acromegaly in adults and very rarely to gi-
gantism in children [28]. Acromegalic patients develop a characteristic facial appearance
with a prominent forehead, prognathism and nasal bone hypertrophy. Often, patients ob-
serve an increase in ring or shoe size due to acral enlargement. Additionally, acromegaly
is connected to a variety of other clinical features which are summarized in table 2.2. Be-
cause symptoms are so diverse and often unspecific, diagnosis is often delayed for many
years [29]. A recent meta-analysis demonstrated that the mortality rate of acromegalic
patients is increased by 72% compared to the general population [30].
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System Clinical feature
Bone and joint Acral changes, gigantism, prognathism, arthritis,
osteopenia, carpal tunnel syndrome
Heart Cardiomyopathy, hypertension, arrhythmias, valvulopathy,
heart failure
Thyroid Goiter
Skin Tags, excessive oily perspiration
Pancreas Glucose intolerance, diabetes
Lung Obstructive sleep apnea
Kidney Antinatriuresis, fluid retention, increased aldosterone, renal
failure
Gonads Hypogonadism
Muscle Proximal myopathy
Colon Polyps
Fat Lipolysis
Visceromegaly Tongue, thyroid, salivary gland, liver, spleen, kidney,
prostate
Table 2.2. Clinical manifestations of acromegaly.
Table modified after [31]. Listing is not exhaustive.
Lactotroph Adenomas
Adenomas that secrete prolactine, so called prolactinomas, represent the majority of
pituitary neoplasms [23]. The most frequently encountered clinical manifestations in-
clude galactorrhea, amenorrhea, infertility and sexual dysfunction. Prolactinomas occur
significantly more often in women than in men [32, 33]
Adrenocorticotroph Adenomas
Oversecretion of ACTH and consequently high levels of cortisol result in a variety of
clinical symptoms, which are generally referred to as Cushing’s disease. Patients have
a characteristical fat distribution pattern. Fat pads arise particularly centripetal, such
as in the abdominal region as well as dorsocervical and supraclavicular, causing the
typical buffalo hump and a moon face [34]. Constantly elevated cortisol levels also cause
numerous other symptoms that are shown in table 2.3.
Thyrotroph Adenomas
Thyrotroph adenomas are very rare tumors that produce an excess of TSH and accord-
ingly stimulate growth and hormone production of the thyroid gland. 93% of patients
develop a goiter and 70% present with thyroid nodules, but signs of hyperthyroidism are
mostly moderate [36, 37]. Frequently, patients are misdiagnosed and 25% are erroneously
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thyroidectomied [38].
Gonadotrop Adenomas
Clinical signs of an excess of hormone secretion are only rarely observed in gonadotroph
adenomas. Instead, patients suffer from visual loss, symptoms of hypopituitarism and
headache as consequences of the mass effects of the usually very large tumors [39].
Gonadotropinomas were reported to secrete functional or nonfunctional FSH or in rare
cases LH, leading to different clinical pictures such as ovarian hyperstimulation syndrome
in females or hypogonadism in males [40, 41]
Non-functioning Pituitary Adenomas
Clinically non-functioning pituitary adenomas (NFPA) represent an inhomogenous group
of tumors. In fact, they are histologically different tumor entities which do not cause
symptoms of hormonal oversecretion. Immunohistochemical analyses revealed that 64%
of NFPA are silent gonadotroph adenomas, followed by 18% null cell adenomas and
12% silent corticotroph adenomas [42]. Although NFPA are considered clinically ’non-
functioning’ they often secrete hormones. A study with 22 NFPA showed that 19 were
producing gonadotropins or subunits, but apparently this does not come to clinical
presentation [43]. Instead, patients with NFPA usually present with symptoms related
to compression of local structures. Besides that, NFPA are frequently seen as incidental
findings on brain radiographs [26].
System Clinical feature
Bone Osteoporosis
Heart Hypertension
Skin Facial plethora, violaceus striae wider than 1cm, acne,
hirsutism, thinning
Pancreas Glucose intolerance, diabetes
Muscle Proximal muscle weakness
Fat Central obesity, sudden weight gain
Gonads Decreased libido, impotence, menstrual disorders
Immune system Recurrent opportunistic or bacterial infections
Psyche Depression, psychosis
Table 2.3. Clinical manifestations of Cushing’s disease.
Table modified after [35]. Listing is not exhaustive.
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Atypical Pituitary Adenomas and Pituitary Carcinomas
In addition to the above mentioned typical pituitary adenomas, numerous tumors that
demonstrate highly aggressive behavior are classified as atypical. Up to 55% of pituitary
adenomas are reported to be invasive to local structures like the dura, bone and other sur-
rounding tissues [44]. The clinical course of atypical pituitary adenomas is characterized
by resistance to current treatment regimens and by frequent recurrence. The 2004 WHO
classification defines atypical adenomas by invasive growth, a Ki-67 labeling index > 3%,
extensive p53 immunoreactivity and a high mitotic index [6]. While atypical adenomas
are seen in even 15% of surgically treated tumors [45], pituitary carcinomas are still
exceptional. Table 2.4 shows 179 published cases of pituitary carcinomas. Considering
the data from table 2.4, the most prevalent carcinoma subtypes are adrenocorticotroph
and lactotroph.
Tumor type Colao et al. 2010[46] Since 2010 Total
ACTH 61 11
[47, 48, 49, 50, 51, 52, 53, 54]
72
PRL 53 7
[55, 51, 53]
60
GH 9 1
[56]
10
FSH/LH 8 0 8
TSH 2 1
[57]
3
Non-functioning 17 9
[58, 59, 51, 60, 61]
26
179
Table 2.4. Reported cases of pituitary carcinomas
Table adapted from [46].
For the diagnosis of a pituitary carcinoma, the presence of metastases is strictly re-
quired [6]. The sites of metastases are rather systemic than craniospinal [62]. The
evolution of pituitary carcinomas is still uncertain. Different theories suggest previous
radiotherapy, effects of surgery or transformation out of a benign adenoma to cause
progression to malignity. Recent publications presented evidence to suggest the latter
hypothesis [46, 44]. This is supported by the fact that the latency period between the
presentation with an adenoma until the development of metastases varies from 4 months
to 18 years (mean 6.6 years) [62].
The prognosis of metastasized pituitary tumors is poor. 66% of patients die within
the first year after diagnosis [62]. In the past, considerable efforts were made to identify
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markers for the prediction of malignant progression. Several markers like Galectin-3,
increased expression of telomerase or Ki-67 labeling index above 10% have been sug-
gested. Recently, repeated histopathological investigations in resected pituitary tumors
revealed the loss of the MSH6 protein to be a factor of adenoma to carcinoma transfor-
mation in pituitary tumors under temozolomide treatment [55, 51]. Nevertheless none
of those markers seems to be applicable to all carcinomas and so the exact mechanisms
of progression to malignity remain unclear [46, 63, 6, 44].
2.1.2.3. Current Treatment Options for Pituitary Tumors
Pituitary tumors can be treated in many different ways, depending on their histological
subtype and their clinical presentation. The aims of all treatment approaches are to i)
reduce tumor mass, ii) normalize hormone levels, iii) recover normal pituitary function
and iv) prevent the formation of metastases.
Surgery
Surgical treatment of pituitary neoplasms is the first line treatment for all pituitary
neoplasms except prolactinomas. The advantages of a surgical intervention are an in-
expensive and rapid relief from symptoms and the possibility to obtain tumor mate-
rial for histological characterization [64]. Two techniques are currently performed: the
transsphenoidal approach, which is preferred in 90 to 95% of cases and the more inva-
sive transcranial approach [65]. The remission rates after transsphenoidal surgery vary
between 54% and 70% depending on the criteria used for the definition of ’remission’,
the experience of the surgeon and the selection of adenomas [65]. Though the mortality
rate in transsphenoidal surgery is quite low (0,9%), complications like (transient) ante-
rior pituitary insufficiency and diabetes insipidus occur frequently (19,4% and 17,8%)
[66]. Transcranial surgery is used in cases where size or extension of the tumor render a
transsphenoidal approach impossible [67].
Radiotherapy
The goals of radiotherapy regarding the treatment of pituitary tumors lies primarily in
the treatment of tumor recurrence as well as the removal of non-surgically resectable
residues. 10 years after completion of radiotherapy, tumor growth was locally controlled
in up to 98% of tumors, depending on the tumor type [68]. Effects of radiation therapy
emerge only with a considerable time delay of 6 to 10 years on average [69]. Delivery
of radiation can be carried out either as a high single dose treatment or it can be frac-
tionated into many sessions with smaller doses. In terms of efficacy, both ways perform
equally well [70]. The single dose approach, also called stereotactic radiosurgery, is more
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convenient to the patient, as it requires only one visit, but achievement of hormonal con-
trol might be slow. The conventional fractionated radiotherapy appears to be superior in
cases where the tumor lies close to the optic chiasm, because it is more gentle to the sur-
rounding tissue [69]. Side effects of radiotherapy include development of hypopituitarism
after several years, an increased risk for stroke and optic neuropathy. Around 50% of
patients treated with radiotherapy for pituitary adenomas require hormone replacement
therapy after 19 years [71].
Dopamine Agonists
Dopamine agonists mediate their antiproliferative and hormone suppressive effects via
the D2 and D1 dopamine receptors of pituitary cells. The currently most used com-
pounds are cabergoline, bromocriptin and quinagolid. Dopamine agonists are the treat-
ment of choice in the therapy of prolactinomas. Cabergoline normalized prolactin levels
in 86% of patients in a large study with 455 patients [72]. A reduction in tumor mass
(i.e. more than 20% change to basal) was reported in more than 80% of patients [73].
Relief from compressive effects of the tumor is experienced after several days of treat-
ment. In other types of adenomas, dopamine agonists show some effect, but their use is
restricted to cases where other treatment options fail. In patients with growth hormone
producing adenomas, cabergoline was proven to be effective in suppressing GH below
2μg/L in 46% and tumor shrinkage was observed in 13 of 21 patients [74]. In the case of
corticotroph adenomas, a hormonal control rate of 40% after two years administration of
cabergoline has recently been demonstrated [75]. In NFPA, dopamine agonists achieved
a reduction of tumor size in approximately 27,6% of cases [76] whereas in thyrotroph
adenomas, there is no clear evidence for a benefit [36]. The most common side-effects of
dopamine agonist therapy are nausea and vomiting, postural hypotension and headache.
Special attention must be given to the development of cardiac valve disease in very rare
cases [77].
Somatostatin Analogs
Somatostatin analogs act mainly on the somatostatin receptor subtypes 2 and 5. The
presently available drugs are octreotide, lanreotide and pasireotide. These drugs are
mainly used in the treatment of acromegaly, in which case they were shown to suppress
growth hormone levels below 2 μg/L in 60-70% and to normalize IGF-1 levels in 50-80 %
of patients [78]. Reduction of tumor size by somatostatin analogues varies between 20
and 70% of acromegalic patients [78]. In patients with thyrotroph adenomas, a more
than 30% reduction in fT4 and fT3 blood levels could be achieved with octreotide in 7
of 8 patients [79]. In patients with NFPA, a decrease in tumor volume was seen in only
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12% [76] and in patients with prolactinomas, somatostatin analogs were not effective in
lowering prolactin levels [80]. Only recently, a phase III trial with the somatostatin ana-
log pasireotide for the treatment of Cushing’s disease showed, that 50 of 103 patients had
a reduction of more than 50% of their baseline cortisol levels[81]. This strong effect on
cortisol levels is attributed to the comparable high affinity of pasireotide to the somato-
statin receptor subtypes 5, which is strongly expressed in adrenocorticotroph adenoma
[82, 83]. The most common side effects of somatostatin analogs are gastrointestinal
disturbances, gall stones and impaired glucose tolerance [84].
Other Methods Of Treatment
Besides the aforementioned established treatment options, several therapies have been
applied to reduce the impact of symptoms: Pegvisomant is a growth hormone analog that
blocks the peripheral action of growth hormone and it is used as a third line treatment
in acromegaly[85]. For the treatment of Cushing’s disease bilateral adrenalectomy and
the use of inhibitors of steroidogenesis such as Ketokonazol, Metyrapone, Mitotane and
the only recently discovered compound LCI699 represent third line treatment options
that effectively control hypercortisolism [86, 87]. However, all these treatment options
are directed towards the peripheral hormonal control and cannot control tumor size. In
TSH secreting adenomas thyroidectomy and antithyroid drugs such as thiamazol and
propylthiouracil were shown to reduce symptoms of hyperthyroidism.
2.2. Temozolomide
2.2.1. Metabolism
Temozolomide is an imidazotetrazine and stable in acidic solutions. Its pharmacologi-
cal importance is based on its usage as a methylating agent that can methylate nucleic
acids such as DNA. The molecular mechanism of action involves the formation of reactive
methyldiazonium ion in aqueous solutions and the consecutive methylation of DNA by
this reactive species (see figure 2.2). Temozolomide is activated spontaneously in aque-
ous solutions with physiological pH by hydrolysis of the tetrazine ring structure and
the formation of monomethyl triazenoimidazole carbocamide (MTIC). Acidic catalyzed
hydrolysis of MTIC forms a stable amino imidazole carboxamide (AIC) and a reactive
methyldiazonium ion [88, 89]. This reactive species contains an electrophilic methyl
group that reacts with nucleophilic groups, such as O6 and N7 of guanosine as well
as N3 of adenosine (see figure 2.2). Due to the above described molecular mechanisms,
temozolomide possesses properties that render it well-suited for medical applications. As
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Figure 2.2. DNA methylation by temozolomide
a) Temozolomide is activated upon reacting with water leading to the release of the reactive species,
methyldiazonium ions. b) The released methyldiazonium ions methylate various biomolecules, among
which are different DNA bases. Here, the methylations of adenosine and guanosine are illustrated.
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the first step of activation is inefficient in acidic solutions, temozolomide is not affected
by the stomach passage and can thus be given orally. In contrast to other methylat-
ing agents, such as the structural analogue dacarbazine, the formation of MTIC occurs
spontaneously and, in particular, does not require hepatic metabolism. Furthermore,
studies of temozolomide have shown promising biokinetic properties such as an oral
bioavailabilitiy of 100% [90], a time to maximal plasma concentration of approximately
1 h (0,33-2,5 h) and a serum half-life of 109min [91]. Considering that the simultane-
ous consumption of food results in a 9% reduction of absorption [92], the drug should
consequently be taken in a fasting state. The biodistribution of temozolomide is satis-
factory as it crosses the blood-brain barrier readily and reaches concentrations of 2,9 to
6,7 µg/ml in human brain tumors [93]. The main excretion of temozolomide occurs via
the urine, wherein 5,5% of the dose are excreted as the original compound, 12% as AIC
and the rest in smaller degradation products [94]. As schedule dependency of temozolo-
mide treatment due to depletion of MGMT has been demonstrated [95, 96], different
treatment schedules have been suggested so far [97]. Most studies apply the schedule
proposed in the phase 1 trial: Temozolomide is given in a 5 day course with a daily dose
of 150mg/m2 in the first course. If there is no considerable myelotoxicity observed at
day 22 of treatment, the following courses are given with 200mg/m2daily dose. Cycles of
treatment are repeated every 4 weeks [90]. Other possible schedules include dose dense
regimens with comparable low doses (50-150mg/m2) of temozolomide for longer time
periods (7-28 subsequent days) [98].
2.2.2. Cellular Mechanism of Action
Temozolomide is an alkylating drug and its application leads to several products of
DNA methylation (see figure 2.3). The methylation sites of temozolomide are N7 of
guanin, N3 of adenine and O6 of guanine and methylation efficiency was found to be
70%, 9.2% and 5%, respectively [89]. Like every other DNA damage, DNA methylation
severly impacts cellular processes such as DNA replication. Consequently several DNA
repair mechanisms can be found in human cells. The repair efficiency of the different
mechanisms determines the severity of the respective DNA damage. In the context
of temozolomide induced methylation, three different repair mechanisms need to be
considered.
Base Excision Repair
The lesions at the N3 of adenine and the N7 of guanine, which represent the major
part of the methylated bases, are removed completely by the base excision repair [99].
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Consequently, methylation at these sites is cytotoxic only in cases where base excision
repair is defective [100] or saturated by very high concentrations of temozolomide [101].
Potentiation of the cytotoxicity of these lesions can be achieved by inhibition of the base
excision repair.
Mismatch Repair
The methylation at the O6 site of guanine is the main cause for the cytotoxicity of
temozolomide, although it represents only 5% of the methylated bases [102]. Methy-
lated guanine mispairs with thymine instead of cytosine because this pairing provides less
distortion to the DNA strand [103]. In the first replication phase, the O6-methylguanine-
cytosine pair is readily replicated, resulting in an intact double strand carrying a G/C
pair and the methylated strand carrying the O6-methylG/T pair. In the second S-
phase, the mismatch repair removes the mispaired thymine as well as several up- and
downstream nucleotides before a new complimentary strand is synthesized [104] (see
figure 2.3). This effort is doomed to failure, because no perfectly matching base can
be found for the O6-methylguanine [105]. Consequently the mismatch repair repeat-
edly attempts to fill the gap and replication of the DNA is unable to advance. In
mismatch repair proficient cells, increased DNA synthesis is observed, reflecting the fu-
tile attempt of mismatch repair in processing the methylated base [106]. As a result,
O6-methylation of guanine leads to G:C to A:T transitions, single- and double-strand
breaks, sister chromatid exchanges and eventually to a stop of DNA replication and
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BER refers to Base excision repair and MMR to Mismatch repair.
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apoptosis [107]. Comparative studies in mismatch proficient and deficient cell lines show
that cells with a non-functional mismatch repair are more tolerant to effects induced by
O6-methylguanine lesions [106, 108].
Alkyltransferase-Mediated DNA Repair
A third repair mechanism relies on the enzyme methyl guanine methyl transferase
(MGMT), an alkyltransferase that is involved in the removal of the methyl group at
the O6 position of guanine. Although expression of MGMT is ubiquitous, expression
levels vary between the investigated tissues and among individuals [109]. MGMT trans-
fers the methyl group to an internal cysteine [110]. This step is irreversible and leads to
the ubiquitination and depletion of the enzyme after prolonged temozolomide adminis-
tration [96, 111]. The presence of high levels of MGMT can therefore promote tolerance
to temozolomide treatment, because the toxic lesion is removed by the enzyme.
In a study by Wang et al. 86,3% of 197 pituitary tumors were found to have low
MGMT levels [112]. Prolactinomas exhibited the lowest levels of MGMT expression
[113]. In the treatment of glioblastomas, the level of MGMT expression is predictive
for the response to temozolomide [114]. The applicability of MGMT status to predict
response to temozolomide in pituitary adenomas is still a matter of discussion. A recent
review found 17 of 22 pituitary adenomas with low MGMT expression responsive to
temozolomide treatment, whereas 3 of 3 pituitary adenomas with high MGMT expres-
sion showed a poor response [115] (see also tables 2.5 and 2.6). Despite of that, there
are several limitations to the general application of MGMT levels as an indicator whom
to treat and not to treat with temozolomide: Exact cut-off values for low or high expres-
sion as well as definition of response or failure of drug treatment are not well defined.
Furthermore there are tumors with high MGMT expression that showed good response
to temozolomide and there are cases where poor response was observed though MGMT
level was low [97]. Table 2.5 highlights the negative correlation between reported re-
sponse rates of pituitary adenomas that have already been treated with temozolomide
and their MGMT expression level.
There are two commonly used techniques for the determination of MGMT expres-
sion levels: immunohistochemistry and promoter methylation analysis. Studies showed
that the correlation between the two methods as well as the correlation of the deter-
mined MGMT levels with treatment outcome is not satisfactory [116, 117] (See appendix
A). The currently preferred method to determine MGMT levels for pituitary tumors
is immunohistochemistry. Compared to the analysis of MGMT promoter methylation,
MGMT expression determined by immunohistochemistry was superior regarding the pre-
diction of temozolomide sensitivity in 16 cell lines [118]. In the case of glioblastomas,
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MGMT promoter methylation is the method of choice of determining temozolomide
responsiveness [119].
Recent studies analyzed potential mechanisms to enhance the cytotoxicity of temo-
zolomide by depleting MGMT from the cells. With the discovery of O6-benzylguanine
and O6-bromothenylguanine two potent inhibitors of MGMT were identified and combi-
nation of treatment with temozolomide is currently investigated [101] (compare chapter
2.2.3). A twice daily temozolomide regimen has also been proved as another mechanism
of depleting MGMT without an increase in toxicity [120].
Role of MSH6 in the Context of Mismach Repair
MSH6 is a protein involved in mismatch repair. Together with MSH2 it forms a com-
plex that recognizes DNA damage and promotes DNA repair. In vitro it has already
been shown that inactivation of MSH6 mediates resistance to alkylating drugs since
mismatch repair is no longer recognizing DNA mismatches. The lethal effects of alky-
lating drugs like temozolomide are therefore averted (Compare chapter 2.2.2). Hunter
et al. were the first to report that in vivo MSH6 mutations arise in glioblastoma after
temozolomide treatment as a consequence of clonal evolution [121]. These observations
have been supported by two other studies: MSH6 inactivation in previously MSH6 pro-
ficient tumors was strongly associated with tumor recurrence [122, 123]. Inactivation
of mismatch repair in vitro resulted in hypermutability, hence promoting cell growth
and leading to drug resistance [124]. Treatment with alkylating drugs seems to produce
selection pressure on the cells. In vitro, it could be observed that MSH6 deficient cells
showed a markedly enhanced growth under temozolomide treatment, compared to MSH6
proficient cells [122]. In 2011, Murakami et al. described the first pituitary adenoma
acquiring temozolomide resistance due to MSH6 inactivation. The previously MSH6
immunopositive atypical prolactinoma progressed to a MSH6 immunonegative pituitary
Adenoma
MGMT activity High Intermediate Low Unknown Total
+ - + - + - + -
PRL 1 3 1 0 10 4 4 1 24
ACTH 3 4 0 0 6 1 3 1 18
GH 0 2 1 0 0 0 0 1 4
FSH/LH 0 0 2 0 0 0 0 1 3
NFPA 5 5 0 0 2 1 3 2 18
Total 9 14 4 0 18 6 10 6 67
Table 2.5. Temozolomide efficacy in pituitary adenomas
+= response to TMZ, - = no response to TMZ; MGMT staining: <10%=Low, 11-50%=Intermediate,
>51%=High. Status on April 15, 2015.
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carcinoma [55]. Hereafter, a Japanese group retrospectively analyzed 13 tumor samples
of patients with pituitary adenomas who were treated with temozolomide. They found a
strong correlation between resistance to temozolomide treatment and absence of MSH6
immunostaining. All three of the adenomas with a progressive disease were immunoneg-
ative and all three adenomas with a complete response showed high immunopositivity
for MSH6 (50% or above). Only one patient with negative MSH6 staining had an initial
response for nine months. The remaining six adenomas with partial response or stable
disease showed intermediate to high immunostaining [125, 51]. The findings from the
glioblastomas as well as the pituitary adenomas investigated so far suggest that MSH6
inactivation is independent of MGMT status and p53 mutations [126, 51]. These ob-
servations strongly suggest MSH6 to become an important factor to predict response to
temozolomide treatment and moreover, MSH 6 is a promising target for future research
in temozolomide resistant tumors.
2.2.3. Clinical Application of Temozolomide
After the first chemical synthesis of temozolomide in 1984 by Stevens et al. [127] and
the phase I trial by Newlands et al. in 1992 [90], the efficacy of temozolomide treatment
was tested in a huge variety of tumors and combined therapies were assessed with many
different compounds. Due to its structural and functional similarity to dacarbazine,
which has previously been used in the treatment of metastatic melanoma, temozolomide
was investigated as a potential alternative to dacarbazine in melanoma therapy. A con-
sequent study showed equal effectiveness to dacarbazine [128] and additional superiority
in the treatment of brain metastases [129]. Today temozolomide is well integrated in
the standard therapeutic strategy of metastatic melanoma [130]. Because of its good
biodistribution and ability to pass the blood-brain barrier, the efficacy of temozolomide
in malignant brain tumors was assessed in the phase I trial. In this study, responsive-
ness to temozolomide was observed in 2 of 4 high grade gliomas [90]. Since then, several
studies have investigated the usage of temozolomide in the treatment of glioblastomas
[131, 132, 133, 134]. The combination of temozolomide and radiotherapy became stan-
dard of care in many places after the study of Stupp et al. was released in 2005. The
study analyzed the benefits of concomitant temozolomide treatment in radiotherapy and
showed that the combined therapy increased the two-year survival rate from 10,4% to
26,5% [135].
Clinical trials with temozolomide have been performed in many tumor entities includ-
ing: hematologic neoplasms, carcinomas, sarcomas, neuroendocrine tumors and different
sorts of brain tumors [136]. But up to date, FDA and EMA approval of temozolomide
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is restricted to anaplastic astrocytoma and newly diagnosed glioblastoma multiforme in
combination with radiotherapy [137, 138].
Recent treatment strategies focus on the potentiation of temozolomide toxicity with
other agents. The major role is attributed towards the disabling of two mechanisms of
temozolomide resistance, i.e. inactivation of MGMT and base excision repair:
O6-benzylguanine acts as a false substrate to MGMT. Due to its structural similarities
to the natural substrate O6-methylguanine, the MGMT enzyme binds to the benzyl
group from O6-benzylguanine. This is an irreversible step and leads to the degradation
of MGMT [139]. The use of temozolomide with concomitant O6-benzylguanine has
been evaluated in several studies, but showed only little success [140, 141]. Another
representative of MGMT inhibitors is the oral available agent O6-bromothenylguanine,
which is ten times more potent than O6-benzylguanine [142]. However, no convincing
benefits of the combination with temozolomide have been shown so far [143].
The second mechanism of temozolomide enhancement is the inhibition of poly (ADP-
ribose) polymerase (PARP). The physiological function of PARP is to detect and bind to
DNA damage. Subsequently it starts to recruit other enzymes involved in base excision
repair [144]. Through the inhibition of PARP, the temozolomide induced methylation at
N7-guanine and N3-adenine cannot be repaired anymore. The lesions that had previously
sufficiently been repaired by the base excision repair can now contribute to temozolomide
induced toxicity. The efficacy of PARP inhibitors in many tumor types is currently
investigated in phase II trials. The combination of the PARP inhibitor ABT-888 and
temozolomide has demonstrated good efficacy in temozolomide resistant tumor tissues
[145].
A very recent development is the combination of temozolomide and the thymidylate
synthase inhibitor capecitabine. The combination has first been approved by Strosberg
et al. in neuroendocrine tumors and had showed good efficacy with good tolerability
[146]. Gulati et al. first successfully applied this regimen to a pituitary tumor of a
patient with a MEN1 associated prolactin secreting pituitary adenoma. The group found
that a pretreatment with capecitabine enhanced toxicity, while cotreatment showed less
synergistic effects. The reasons therefore remain still unclear [147].
Another promising substance for future combination treatments is pyrimethamine, an
inhibitor of folic acid synthesis which is currently used for the treatment of malaria.
After it was first described to improve temozolomide toxicity in melanoma cells [148],
a consequent study in mice bearing GH3-tumor xenografts showed that pyrimethamine
inhibited tumor growth, lowered hormone levels and provided improved survival to the
mice [149]. Many other therapies have been evaluated for the concomitant use with
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temozolomide which are summarized in figure 2.4. [142]
Temozolomide
Antiangiogenic agents
•Cilenglitide
•Bevacizumab
•Thalidomide
Inhibitors of DNA 
repair
•MGMT inhibitors
•PARP inhibitors
Radiotherapy
Zytostatics
•Platin analogues
•Topoisomerase inhibitors
•Taxanes
•Alkylating agents
•Thymidilate synthase 
inhibitors
Immunomodulatory
agents
•Tyrosin kinase inhibitors
•Interferon beta
•Rituximab
Others
•Folic acid synthesis
inhibitors
Figure 2.4. Therapeutic combinations with temozolomide.
Temozolomide can be combined with several other forms of treatment in order to achieve a maximal
tumor response. Figure modified after [142].
2.2.4. Usage of Temozolomide in Treatment of Pituitary Tumors
The first use of temozolomide was reported by Zhu et al. at the annual meeting of
the US Endocrine Society in 2004. They described the case of a 61-year old patient
with a prolactin producing carcinoma, that responded to temozolomide with tumor
shrinkage, reduction in hormone level and clinical improvement [150]. Two years later,
other groups started to use temozolomide in treatment resistant, aggressive pituitary
adenomas and pituitary carcinomas. In 2006 and 2007, five successful reports were
published. These observations gave rise to larger case series in the following years. A
detailed list of all published cases of temozolomide treated pituitary tumors is shown in
appendix A. Until date, 103 cases of the usage of temozolomide in pituitary tumors have
been documented. The median patient age was 45 years, with the youngest being 1 and
the oldest 73 years old. Tolerability seemed to be good, comparable to that seen under
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temozolomide in the treatment of other tumors. The tumors that were deemed applicable
to a trial of temozolomide treatment in the literature were mostly aggressive in nature.
Many showed locally invasive behavior, multiple recurrences and resistance to previous
treatment options. 36 of the patients had pituitary carcinomas. The response rate of
58% (60 of 103 tumors) is convincing, considering that these tumors were treatment
resistant to other therapies (see table 2.5 and table 2.6). Reported response rates were
greater in the beginning, probably due to “reporting bias”. Subsequent larger case series
found lower response rates. Treated patients usually showed improvement of clinical
signs, reductions in hormone level and tumor shrinkage in brain scans (see figure 2.5 and
appendix A). Tumors also showed changes in morphology after treatment with the drug.
Kovacs et al. reported a case in which temozolomide induced necrosis, hemorrhage and
even neuronal transformation of the tumor [151].
Figure 2.5. Pituitary adenoma pre- and post-treatment
The left scan shows the patient before and the right after temozolomide treatment. A marked reduc-
tion in tumor size can be seen.
Pictures obtained from Hagen et al. [152]
Response to temozolomide was not always permanent. Progression of disease after an
initial response was noticed in several cases [153, 154, 55, 59, 47]. Response rates were
different in the respective tumor types. Prolactin and ACTH producing tumors were
most likely to respond (16 of 24; 66% and 12 of 18; 66%), followed by non-secretory
tumors (10 of 18; 55%). For other tumors, a positive response upon temozolomide
treatment was reported for 1 of 4 growth hormone producing tumors as well as for 2 of
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3 gonadotroph adenomas. Of the four described growth hormone producing tumors 3
showed no response and of the 3 gonadotroph adenomas, 2 responded. No difference in
sensitivity to temozolomide treatment was found among adenomas versus carcinomas.
Furthermore no significant difference in response to temozolomide between female and
male patients has been reported.
18 of 24 adenomas (75%) with low MGMT staining responded to temozolomide, com-
pared to 9 of 23 adenomas (39%) with high MGMT staining. These observations con-
tribute to the hypothesis that response to temozolomide is linked to the presence of
MGMT (See chapter 2.2.2). Regarding the pituitary carcinomas listed in table 2.6, a
promising response rate of 53% (19 of 36) was observed for these aggressive tumors.
In the pituitary carcinomas, MGMT status also seems to play a role as only 2 of 6
carcinomas (32%) with high MGMT expression responded, compared to 8 of 11 (73%)
with low MGMT status. However, in the adenoma group listed in table 2.5 as well as in
the carcinoma group in table 2.6, the MGMT status of many tumors remains unknown,
making a reliable statement difficult.
2.2.5. Adverse Reactions of Temozolomide Treatment
Throughout the therapy with temozolomide, monitoring of hepatic enzymes, renal func-
tion and blood counts should be performed. Elevation of liver enzymes has not been
described in the big clinical trials with temozolomide, but some smaller case series wit-
nessed a moderate increase [155, 156]. Renal function seems not to be affected by the
drug [157]. Concerning the possible teratogenic potential of the drug, appropriate meth-
ods for contraception should be performed. Though evidence for potential fetal harm
has been found in animal models [138], there have been several case reports of healthy
babies, born to mothers on temozolomide treatment. [158]
Carcinoma
MGMT activity High Intermediate Low Unknown Total
+ - + - + - + -
PRL 0 1 0 2 2 1 6 2 14
ACTH 1 2 1 2 4 1 1 3 15
GH 0 1 0 0 1 0 0 0 2
FSH/LH 0 0 0 0 0 0 1 0 1
Non-functioning 1 0 0 0 1 1 0 1 4
Total 2 4 1 4 8 3 8 6 36
Table 2.6. Temozolomide efficacy in pituitary carcinomas
+= response to TMZ, - = no response to TMZ; MGMT staining: <10%=Low, 11-50%=Intermediate,
>51%=High. Status on April 15, 2015.
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Myelotoxicity was the dose limiting factor in the phase I study performed by Newlands
et. al. in 1992 [90]. Lymphopenia evolved in approximately 50% of patients treated
for melanoma or neuroendocrine tumors and cases of opportunistic infections were also
observed [159, 160]. The nadir of lymphopenia is predictable between days 21 and 28 of
treatment and reduction of dose is advisable in these cases.
Due to the occasional occurrence of opportunistic infections with pneumocystis jirovecii,
especially in patients receiving concomitant radiation and steroid therapy, a prophylactic
treatment with Trimethoprim-Sulfamethoxazol is recommended by some clinicians [161].
Considering the incidence of less than 1% of pneumocystis jirovecii pneumoniae and re-
garding the side effect profile of the chemoprophylaxis, its usage is subject to current
discussions [162].
Recently a less common side effect concerning the posterior pituitary lobe has been re-
ported by Faje et. al. [163]. The retrospective study identified 5 patients who developed
central diabetes insipidus limited to the time of temozolomide treatment. Regarding the
potential of temozolomide to induce secondary malignancies, several studies have linked
temozolomide to the development of hematological malignancies such as leukemia [164].
Allergic reactions to temozolomide treatment have been reported [165] but are usually
restricted to cutaneous symptoms.
In summary the most frequent encountered side effects linked to temozolomide use
are fatigue, alopecia, nausea, vomiting, anorexia, headache and constipation [138]. Most
side effects were mild to moderate in degree and usually treatable with appropriate
medication. The dose limiting side effects are leukopenia (2%) and thrombocytopenia
(7%), but less than 1% of patients discontinued treatment due to adverse effects [131].
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Atypical pituitary adenomas account for 8,9% - 15% of all surgically resected pituitary
tumors but to date, no FDA approved therapy for this tumortype and for pituitary
carcinomas exists[45, 166]. Atypical adenomas are usually large tumors that are resis-
tant to dopamine agonists and somatostatin analogs. They demonstrate a high rate of
invasiveness, require multiple surgeries and radiotherapy and show strong tendency to
recur. The same is true for pituitary carcinomas and consequently this aggressive nature
results in a death rate of 66% within the first year after diagnosis [62]. For an optimal
treatment of these tumors there are several main goals: i) control of tumor growth, ii)
control of hormone excess, iii) prevention of metastases and finally iv) preservation of
normal pituitary function. With a percentage of 58% clinical responders in the adenoma
group and 52% among the carcinomas (Compare table 2.5 and table 2.6), temozolomide
has demonstrated good effectiveness even if all other treatment options have failed. Un-
til now, temozolomide induced reduction of proliferation and a hormone reductive effect
for FSH, LH and PRL in pituitary cell lines was demonstrated in two studies [167, 168].
The goal of this thesis was to expand the knowledge of temozolomide induced effects
on pituitary cells. We wanted to investigate the influence on proliferation and hormone
secretion of normal and tumoral pituitary cells of different origin. A special focus was
set on the question whether the observed effects on hormone secretion were simply a
result of mass reduction or due to a specific hormone suppressive effect of temozolomide.
Another question that we wanted to answer was whether we could detect any effect on
metastasizing potential. For answering this question we applied a clonogenic assay and
we investigated the influence on angiogenesis of pituitary tumors.
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4.1. Material
4.1.1. Equipment
Table 4.1. List of equipment used in this study
Product Provider
ARCTIS 1300 GS Refrigerator AEG (Nürnberg, Germany)
Automatic pipet - Pipetus® Hirschmann Laborgeräte (Eberstadt,
Germany)
Autoradiography Cassette - Hypercassette GE Healthcare (Buckinghamshire,
England)
Burner - Fireboy plus Integra Biosciences (Fernwald, Germany)
Cell counter - Scepter™ Handheld
automated Cell Counter
Millipore Corporation (Billerica, MA, USA)
Centrifuge - Biofuge primo Thermo Scientific (Waltham,USA)
Centrifuge - Centrifuge 5415 R Eppendorf (Hamburg, Germany)
Cooling-Thermomixer - KTMR-133 Haep Labor Consult (Bovenden, Germany)
Electrophoresis chamber - Mini Trans
Blot-Cell
Biorad (Hercules, USA)
Electrophoresissystem for gel preparation -
Mini PROTEAN Tetra
Biorad (Hercules, USA)
GTN 2701 Refrigerator Bosch (Munich, Germany)
HFU 586 TOP HERA freeze Refrigerator Thermo Scientific (Waltham,USA)
HFU 686 TOP HERA freeze Refrigerator Thermo Scientific (Waltham,USA)
Icemachine - ZBE-150 Ziegra (Isernhagen, Germany)
Incubator - Heraeus Instruments Type BB
6220 O2
Thermo Scientific (Waltham,USA)
KGK 4585 Refrigerator Liebherr (Biberach an der Riss, Germany)
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Product Provider
KGT 4066 Premium Refrigerator Liebherr (Biberach an der Riss, Germany)
KT 1483 Refrigerator Liebherr (Biberach an der Riss, Germany)
KT 5R 18.1 Refrigerator Siemens (Munich, Germany)
Laminar Flow - LaminAir®HB 2472 Thermo Scientific (Waltham,USA)
Microplatereader - Dynatech MR 5000 Dynex Technologies (Chantilly, USA)
Microscope - IMT-2 Olympus (Hamburg, Germany)
Microwave - HF12M240 Siemens (Munich, Germany)
Multichannel pipet Eppendorf (Hamburg, Germany)
Multipipet - Multipette® plus Eppendorf (Hamburg, Germany)
Neubauer counting chamber Paul Marienfeld GmbH & Co KG
(Lauda-Königshofen, Germany)
Pipet - Reference® variabel Eppendorf (Hamburg, Germany)
Power supply - Power Pac 1000 Biorad (Hercules, USA)
Precision balance - AT261 Mettler Toledo GmbH (Greifensee,
Switzerland)
Scanner - Aficio MP C 3300 RICOH Deutschland GmbH (Hannover,
Germany)
Scintillation counter - LS 6000 IC Beckman Coulter (Krefeld, Germany)
Scraper knife - Scraper Knife 45mm NISAKU KUY TOOLS JAPAN (Niigata,
Japan)
Shaker - Duomax 1030 Heidolph (Schwabach, Germany)
Spectrophotometer - Smart Spec™ Plus Biorad (Hercules, USA)
Suction pump - Type N735.3 AN.18 KNF Neuberger (Freiburg, Germany)
Vortex - Genie 2™ Bender & Hobein AG (Zürich, Switzerland)
Waterbath - Type 1004 Gesellschaft für Laborbedarf (Burgwedel,
Germany)
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4.1.2. Consumables
Table 4.2. List of consumables used in this study
Product Provider
Autoradiography films - Lumi-Film
Chemiluminescent Detection Film
Roche (Indianapolis, USA)
Blotting filter paper 2.5mm thick Invitrogen (Carlsbad, USA)
Cell Culture flasks TPP (Trasadingen, Switzerland)
Cell scraper 13mm TPP (Trasadingen, Switzerland)
Centrifuge tubes TPP (Trasadingen, Switzerland)
Gloves - Semper guard latex powderfree Semperit Technische Produkte GmbH
(Wien, Austria)
Gloves - Semper guard nitril powderfree Semperit Technische Produkte GmbH
(Wien, Austria)
Insulin syringes - Micro Fine+ U-40 Beckton Dickinson (Franklin Lakes, USA)
Multiwell plates Thermo Scientific (Waltham, USA)
Multiwell plates for ELISA - Corning® 96
Well Clear Polystyrene High Bind
Stripwell™ Microplate
Corning B.V. Life Sciences (Amsterdam,
Netherlands)
Nitrocellulosis membrane - Hybond™ ECL GE Healthcare (Buckinghamshire,
England)
Parafilm® Pechiney Plastic Packaging (Menasha,
USA)
Pasteur pipets Roth (Karlsruhe, Germany)
Reaction vessels Eppendorf (Hamburg, Germany)
Serological pipets TPP (Trasadingen, Switzerland)
Tips - epT.I.P.S. Standard Eppendorf (Hamburg, Germany)
Tips for Multipipets Eppendorf (Hamburg, Germany)
Tips for Scepter™ Cell Counter Millipore Corporation (Billerica, MA, USA)
Tubes - PP tubes Greiner Bio-One (Kremsmünster, Austria)
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4.1.3. Reagents
Table 4.3. List of reagents used in this study
Product Provider
3H-Thymidine 1mCi/ml Perkin-Elmer (Boston, USA)
Acetic Acid Merck (Darmstadt, Germany)
Acridine Orange Sigma-Aldrich (Steinheim, Germany)
Acrylamide-Bis Merck (Darmstadt, Germany)
Ammonium Persulfate 30% Sigma-Aldrich (Steinheim, Germany)
Aqua ad iniectabilia Braun (Melsungen, Germany)
Bovine Serum Albumin Roth (Karlsruhe, Germany)
Bromophenol Blue Sigma-Aldrich (Steinheim, Germany)
Chloramine-T hydrate Sigma-Aldrich (Steinheim, Germany)
Cobalt (II) Chloride Sigma-Aldrich (Steinheim, Germany)
Collagenase Type 1 Worthington (Lakewood, NJ, USA)
Copper(II) sulfate (CuSO4) Sigma-Aldrich (Steinheim, Germany)
Corticotropin Releasing Hormone Bachem (Weil am Rhein, Germany)
Crystal Violet Sigma-Aldrich (Steinheim, Germany)
Desoxyribonuklease Sigma-Aldrich (Steinheim, Germany)
Developer Solution Kodak (Stuttgart, Germany)
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich (Steinheim, Germany)
Disodium Hydrogen Phosphate Dihydrate
(Na2·HPO4 2H2O)
Merck (Darmstadt, Germany)
Dulbecco’s Modified Eagle Medium
(DMEM)
Invitrogen (Carlsbad, USA)
DuoSet® ELISA Development System for
human VEGF
R & D Systems (Minneapolis, MN, USA)
ECL ™ Western Blotting Analysis System GE Healthcare (Buckinghamshire,
England)
Ethanol 70% Medizet (Munich, Germany)
Ethidium Bromide 1% Roth (Karlsruhe, Germany)
Ethylenediaminetetraacetic Acid (EDTA) Sigma-Aldrich (Steinheim, Germany)
Fetal Calf Serum (FCS) Invitrogen (Carlsbad, USA)
Ficoll 400 Sigma-Aldrich (Steinheim, Germany)
Fixer Solution Kodak (Stuttgart, Germany)
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Product Provider
Glucosis Roth (Karlsruhe, Germany)
Glutaraldehyde Sigma-Aldrich (Steinheim, Germany)
Glycine Roth (Karlsruhe, Germany)
Growth Hormone Releasing Hormone Bachem (Weil am Rhein, Germany)
Hepes Sigma-Aldrich (Steinheim, Germany)
Hyaluronidase Type II (from sheep testes) Roche (Indianapolis, USA)
Hydrochloric acid Sigma-Aldrich (Steinheim, Germany)
Insuline (from bovine pancreas) Sigma-Aldrich (Steinheim, Germany)
Isopropylalcohol Roth (Karlsruhe, Germany)
L-Glutamine Biochrom AG (Berlin, Germany)
Methanol Roripuran® Roth (Karlsruhe, Germany)
Milk powder Granovita GmbH (Heimerlingen, Germany)
Monopotassium Phosphate (KH2PO4) Sigma-Aldrich (Steinheim, Germany)
Non-essential amino acids solution (x 100) Invitrogen (Carlsbad, USA)
Nonidet P-40 Invitrogen (Carlsbad, USA)
Particin Biochrom AG (Berlin, Germany)
Penicillin/Streptomycin Biochrom AG (Berlin, Germany)
Ponceau S Solution Sigma-Aldrich (Steinheim, Germany)
Potassium chloride (KCl) Merck (Darmstadt, Germany)
Precision Plus Protein™ Dual Color
Standards
Bio-Rad (Hercules, USA)
Protease Inhibitor Cocktail Sigma-Aldrich (Steinheim, Germany)
Reagent Diluent R & D Systems (Minneapolis, MN, USA)
Roti® Load 1 Loading buffer Roth (Karlsruhe, Germany)
Sodium Chloride (NaCl) Roth (Karlsruhe, Germany)
Sodium Deoxycholate Sigma-Aldrich (Steinheim, Germany)
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich (Steinheim, Germany)
Sodium Hydroxide (NaOH) Sigma-Aldrich (Steinheim, Germany)
Sodium Selenite Sigma-Aldrich (Steinheim, Germany)
Stop Solution(2N H2SO4) for ELISA R & D Systems (Minneapolis, MN, USA)
Substrate Solution for ELISA R & D Systems (Minneapolis, MN, USA)
Temozolomide Sigma-Aldrich (Steinheim, Germany)
Tetramethylethylenediamine (TEMED) Sigma-Aldrich (Steinheim, Germany)
Thyreotropine Releasing Hormone Bachem (Weil am Rhein, Germany)
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Product Provider
Transferrin Sigma-Aldrich (Steinheim, Germany)
Trichloroacetic Acid Sigma-Aldrich (Steinheim, Germany)
Triiodo-L-Thronine (T3) Sodium Salt Sigma-Aldrich (Steinheim, Germany)
Tris Pufferan® Roth (Karlsruhe, Germany)
Triton x -100 Roth (Karlsruhe, Germany)
Trypsin Inhibitor Roth (Karlsruhe, Germany)
Trypsin/EDTA Solution (0,25%) Invitrogen (Carlsbad, USA)
Tween® 20 Biochrom AG (Berlin, Germany)
Xylene Cyanol Sigma-Aldrich (Steinheim, Germany)
4.1.4. Buffers And Solutions
Table 4.4. List of buffers and solutions used in this study
Cell Staining Solution 50µl Acridine Orange (200mg/l)
50µl Ethidium Bromide (10mg/l)
900µl PBS
Colony Staining Solution 6% Glutaraldehyde
0.5% Crystal violet (2.3%)
Culture Medium 500ml DMEM
10% FCS
5ml L-Glutamin (200mM)
5ml Penicillin/Streptomycin (10000 U/ml / 10000
µg/ml)
5ml Particin (1%)
HDB+ buffer 25mM Hepes
5mM KCl
0.7mM Disodium Hydrogen Phosphate Dihydrate
10mM Glucose
25µg/ml Particin
105 E/l Penicillin/Streptomycin
Adjusted to pH 7,3
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Mix of collagenases 100ml HDB+ Buffer
370mg Collagenase (1000U/ml)
10mg Hyaluronidase
10mg Trypsin Inhibitor
400mg Bovine Serum Albumin
500ml Desoxyribonuclease
PBS 8g/l Sodium Chloride
0.2g/l Potassium Chloride
1.44g/l Disodium Hydrogen Phosphate Dihydrate
0.2g/l Potassium Phosphate Monobasic
RIPA buffer 50mM Tris Hydrochloric acid pH8
150 µM Sodium Chloride
1% Nonidet P-40 (0,08mM)
0.5% Sodium deoxycholate (>97%)
0.1% SDS (>99,0%)
Running buffer 25mM Tris
192mM Glycin
0.1% SDS
Adjusted to pH 8,3
Stripping Solution 25mM Glycine
1% SDS (>99,0%)
Adjusted to pH 2
TBS (10x) 24.2g Tris
80g Sodium Chloride
Adjusted to pH 7,6
TBST 1000ml TBS (1x)
0.1% Tween® 20 (1.095 g/ml)
Transfer buffer 25mM Tris
192mM Glycine
10% Methanol
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Tumor medium 500ml Culture medium
5ml Non-essential amino acids solution (100x)
500µl Insulin Novo 40 I.E.
2.5mg Transferrin
10µg Triiodo-L-Thronine (T3) Sodium Salt
10µg Sodium Selenite
4.1.5. Antibodies
Table 4.5. List of antibodies used in this study
Product Provider
Anti-mouse IgG (horse HRP linked
Antibody)
Cell Signaling Technology (Danvers,USA)
Anti-human ß-Actin clone C 4 (mouse
monoclonal Antibody)
Millipore (Billerica, USA)
Anti-human HIF - 1 α Antibody (mouse
monoclonal Antibody)
R & D Systems (Minneapolis, MN, USA)
4.2. Methods
4.2.1. Cell culture
4.2.1.1. Cell Culture of Cell Lines AtT-20 and GH3
Both cell lines(AtT-20 and Gh3) are immortalized cell lines and were obtained from the
American Type Culture Collection (Manassas, VA, USA). The GH3 cell line derives from
a prolactin and growth hormone secreting rat tumor and the AtT-20 cell line from an
ACTH secreting mouse tumor. The cell lines were kept in aliquots at -179°C for long-
time storage. For thawing, the tubes were heated up to 37 °C in the water bath and the
cell suspension was diluted with culture medium. This was followed by a centrifugation
with 1200 rpm for 3min at room temperature. The supernatant was discarded and the
pellet resuspended in fresh culture medium.
Cells were kept in 75 cm2 flasks in an incubator with 37 °C, 95% air humidity and 5%
CO2 concentration. All works with the cells were performed under sterile conditions on
an appropriate work bench. The medium was changed and cells splitted every 3 to 4
days according to cell density under the microscope and the color of the medium. This
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was accomplished by removing the old medium and washing the cells with 15ml of PBS.
Then 4ml of trypsin/EDTA solution was added, followed by an incubation time of 3min
in the incubator in order to detach the cells from the flask. If necessary, remaining
attached cells were mobilized by handclaps against the flask. 10ml of culture medium
was added to stop the reaction. The cell suspension was transferred into a 50ml tube
and centrifuged with 1200 rpm at room temperature for 4min. The supernatant was
discarded and cells were resuspended in fresh culture medium. Approximately 1 million
cells per flask were distributed in new flasks and further incubated.
In order to count the cells, an aliquot of the resuspended cells was mixed with staining
solution (50µl of 200mg/l acridine orange and 10mg/l ethidium bromide and 50µl of cell
suspension) and introduced into a Neubauer counting chamber. While acridine orange
is incorporated in viable cells and colors them green, ethidium bromide can only enter
dead cells and causes an orange stain. By counting the green cells of 4 x 16 squares and
multiplication with 2 x 104 the average numbers of cells per milliliter was determined.
All cell assays were performed using either 6-, 48 or 96-well plates. In the case of the
48- and 96-well plates, only the inner wells were used for the assay, while the outer wells
were filled with PBS solution only. Wells on 96-well plates and 48-well plates were filled
with 100µl/well and 500µl/well, respectively. 6-well plates were filled with 2ml/well
for seeding and 1ml/well for consecutive treatment. Before seeding new plates, the cell
density of the corresponding cell suspensions was determined as described above. All
plates were finally covered with the respective plastic lids.
4.2.1.2. Primary Cell Culture of Human Pituitary Adenomas
The tissue of human pituitary adenomas was obtained by transpheniodal surgeries in the
Neurosurgical clinics of the Universitätsklinikum Erlangen and the Klinikum Großhadern
and Klinikum Rechts der Isar in Munich. The utilization of the tissue was approved by
the local ethics committee. The patients were informed about the usage of the extracted
material prior to the surgery and signed a declaration of agreement. Immediately after
extraction, the tissue was transferred into a tube containing cell culture medium and
send to the lab, where it arrived the following day and further preparation was continued.
The tumor was washed several times with HdB+ buffer to eliminate remaining blood
contamination. The tissue was cut with scalpels in a petri dish and transferred into a
tube containing a mixture of collagenases. This tube was incubated in a waterbath at
37 °C and retrieved every 15min to break up the tissue by pipetting it multiple times
with a Pasteur pipet. The reactions of the collagenases were stopped by adding 10ml
culture medium when no more cell debris was observed by the eye, but earliest 1 hour
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after addition of the collagenases. The suspension was centrifuged at 1200 rpm for 4min
at room temperature and the supernatant was discarded. The centrifuged material was
resuspended with 10ml culture medium and centrifugation was repeated. Cells were
resuspended once more and viable tumor cells were counted and seeded using the same
procedure as described above for cell lines. For the seeding and for all further experiments
with the adenoma cells tumor medium as described in the material section was used.
4.2.1.3. Primary Cell Culture of Rat Pituitaries
Besides murine cell lines and primary human adenoma cells, cell assays were also per-
formed with six week old male Sprague Dawley rats. Animals were killed by carbon
dioxide euthanasia and subsequently decapitated in a miniature guillotine. The scalp
was shifted towards the nose so that the skull could be cut on both sides using scis-
sors. The skull was flapped towards the nose and the cerebrum was removed. The
pituitary gland was now lying free in the sella. Under complete removal of the surround-
ing connective tissue it could be withdrawn and stored in HdB+ buffer until further
preparation. When all required pituitary glands were collected, cell preparation was
performed corresponding to the protocol for the human adenomas.
4.2.2. Treatment with Temozolomide
After the respective time of attachment ranging from 3 to 4 days, cells of primary culture
were washed with PBS to remove nonattached cells and cell detritus. In experiments
with cell lines this step was not necessary and the time of attachment was only 24 h.
Afterwards the old medium was pipetted off and replaced with temozolomide - containing
medium solutions. Prior to any further usage the solutions were freshly prepared with
thawed temozolomide aliquots and culture medium which was preheated to 37 °C. All
experiments were performed using several temozolomide concentrations as indicated.
4.2.3. 3H-thymidine Incorporation
The incorporation of Tritium-enriched thymidine (3H-thymidine) was determined as an
indicator of proliferation. Human adenoma cells were seeded in 48-well plates with a
density of 105 cells per well, AtT-20 and GH3 cells with 104 cells per well. Human
primary adenoma cells were simultaneously treated with medium containing temozolo-
mide and 2% 3H-thymidine solution for 24 h at 37 °C, 95% air humidity and 5% carbon
dioxide concentration. Cell lines were incubated for 24 h with temozolomide, followed
by an incubation period of for 4 h with 3H-thymidine. Cells were then precipitated by
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addition of 500 µl/well ice cold 10% trichloroacetic acid for 1 h at 4 °C. After removal
of trichloroacetic acid, cells were washed with PBS and hydrolyzed with a solution con-
taining 0.5M NaOH and 1% Triton X-100 for 24 h at 4 °C. Thereafter plates were gently
vortexed for 5min and the cell suspension of every well was transferred into tubes with
scintillation liquid. The tubes were thoroughly mixed by vortexing and radioactivity
was measured using a scintillation counter.
4.2.4. Colony Formation Assay
The capacity of forming colonies as well as the reduction of cell number was measured
with a clonogenic assay, following the protocol of Franken et al. [169]. Cells were seeded
in 6-well plates with a density of 1 x 103 cells per well for the GH3 cell line and 0.5
x 103 cells per well for the AtT-20 cell line. Due to the long incubation period of 1
or 2 weeks, culture medium with 2% FCS was used. As we investigated two different
settings, cells were left for attachment for either 1 day or 1 week and then treated
with different concentrations of temozolomide for 2 or 1 weeks, respectively. Change
of medium was performed according to the pH-indicating color of the culture medium
approximately every 3 days. The cells were first washed with PBS and then stained for
30min with a solution containing 6% glutaraldehyde and 0.5% crystal violet. Staining
solution was removed, plates were washed two times with water and then left to dry
at room temperature in normal air. To count the colonies, plates were scanned with
200 dpi as a jpg file and colors were adjusted to a grey scale using Adobe Photoshop.
At a magnification of 120% the colonies of one well of each plate were first counted
manually. Parameters for threshold and minimum were adjusted so that the automated
count of the Clono program [170] matched the manually counted colony number of this
well. These parameters were used to count the rest of the scanned plate by the program.
4.2.5. Cell Counting
In order to obtain exact cell numbers for each well and to still have the possibility
to measure the hormone concentration in the respective well after the cell count, the
handheld Scepter® cell counter was used. The Scepter® cell counter is able to count cells
using an impedance-based method, where cells are aspirated and the change of electrical
resistance when a cell is passing the sensor is registered and counted. Cells were seeded
in 48-well plates with a density of 1 x 105 cells per well and left for attachment for 24 h.
Stimulation with different concentrations of temozolomide was performed for 24 h. The
wells were washed with PBS and solubilized with 250µl trypsin/EDTA solution per well
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for 10min at 37 °C in the incubator. Trypsinization was stopped by the addition of
750 µl culture medium per well. The content of each well was mixed by pipetting up and
down right before measuring it with the Scepter®.
4.2.6. Hormone Measurement using Radioimmunoassay (RIA)
The secretion of ACTH, GH, PRL and TSH were measured for different cell types. For
each hormone that was investigated, a labelled equivalent was needed. In the case of
the ACTH measurement labeling of the antigen had to be performed prior to the RIA.
The other hormones, which had to be artificially tyrosinated before where purchased as
kits from Dr. Parlow, National Hormone & Peptide Programme, Harbor-UCLA Medical
Center, CA, USA.
4.2.6.1. ACTH 125I Labeling
10µl of ACTH standard was diluted with 90 µl of 0.05M phosphate buffer and 5µl of this
solution was given into a siliconized glass tube. Subsequently 25mg Chloramine T as
well as 25mg sodium bisulfate were dissolved each in 8ml 0.05M phosphate buffer. 10 µl
of radioactive iodine (125I) was mixed with 20 µl of 0.5M phosphate buffer and added
into the glass tube together with the solved Chloramine T. The glass tube was vortexed
for 5 s and the reaction was stopped by adding the previouly dissolved sodium bisulfate
and vortexing for 5 s. Chloramine T oxidizes iodine and therby acts as an activator
for the 125I by facilitating the iodination of the aromatic system of tyrosine residues in
ACTH. In contrast, sodium bisulfate reduces iodine to form iodide and therefore stopps
iodination of tyrosine side chains. In order to prevent attachment to the glass, 1ml
10% FCS in culture medium was added. Next, separation of the excessive iodine and
the iodinated ACTH was achieved by vortexing the glass tube with 5mg CUSO for
1min and centrifuging for 30 s. Like that, the ACTH attached to the CUSO and was
spun down. The supernatant was discarded and the pellet was washed with 1ml 0.05M
phosphate buffer. ACTH was eluted from CUSO with 300 µl elution solution, vortexed
for 2min and centrifuged for 2min. The supernatant was immediately transferred in
8ml of buffer A, aliquoted in 1ml eppendorf tubes and frozen at 20 °C.
4.2.6.2. Binding of Antibodies
Prior to the measurement, approximately five random samples were taken from one 48-
well plate. The approximate hormone concentration in these samples was determined in
order to make sure if a dilution step needs to be conducted prior to the actual measure-
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ment. The following steps are based on a competitive principle. For the measurement, a
known amount of radiolabeled antigens was mixed with the appropriately diluted tumor
antigen. The respective primary antibodies were added and the tubes were incubated
at room temperature for 24 hours. This allowed for a competitive binding of the labeled
and unlabeled antigen to the limited number of binding sites of the antibody. The more
antigens the sample contained, the less radiolabeled antigen was bound to the primary
antibody. Then, a secondary antibody, directed towards the Fc part of the primary an-
tibody was added. This step led to the precipitation of the antigen-antibody-antibody
complexes. After centrifugation and disposal of the unbound antibodies and antigens in
the supernatant, samples were resolved. Radioactivity was measured using a γ-counter.
In parallel, dilutions with known concentrations of the respective hormone antigen were
prepared and measured using the same procedure as described above. A standard bind-
ing curve was established for each hormone and the respective hormone concentration
was calculated according to the curve.
4.2.7. Measurement of VEGF-production using ELISA
Cellular expression levels of VEGF were measured with an ELISA Kit (R&D Systems,
MN, USA) according to the manufacturer’s instructions following the principle of a
sandwich ELISA. Cells were seeded in 48-well plates with 1 x 105 cells per well and
grown for 24 h before being treated with different concentrations of temozolomide. A
set of experiments was performed with an additional stimulation of 125 µM cobalt (II)
chloride, which has previously been shown to increase basal VEGF production [171].
After 24 h of stimulation by temozolomide, plates were stored at -70 °C until further
usage. Fresh 96-well ELISA plates were incubated overnight at room temperature with
100 µl anti-human VEGF antibody (1 µg/ml) per well and plates were covered with
Parafilm®. After incubation, wells were washed three times with 400 µl Wash Buffer using
a multichannel pipette. After each washing step, plates were tapped against a paper
towel to ensure proper removal of the Wash Buffer. Subsequently, 300 µl Reagent Diluent
per well was added, followed by an incubation time of 1 h at room temperature and three
more washing steps as performed before. Seven VEGF standards with concentrations
ranging from 31,25 pg/ml to 2000 pg/ml were prepared. 100 µl of the thawed samples or
standards were added to each well, plates were covered with Parafilm® and left for 2 h at
room temperature. Plates were washed three times as described previously and 100 µl of
the Detection Antibody (100 ng/ml) was added and plates covered and left to incubate
at room temperature for 2 h. After another three washing steps, plates were incubated
with 100µl of Streptavidin-HRP (5µl/ml) per well for 20min at room temperature and
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under light protection. Three more washing steps were performed and then 100 µl of
Substrate Solution was added to each well and plates were left to incubate under light
protection. The HRP-catalyzed reaction was stopped by adding 50 µl Stop Solution to
each well. Plates were gently mixed and absorption at 450 nm was determined by an
ELISA plate reader while absorption values at 550 nm were subtracted to achieve higher
accuracy. The plate reader fitted a standard curve for each plate and calculated VEGF
concentrations of each sample according to this curve.
4.2.8. Measurement of Hif-1α-secretion using Western Blot
The production of the transcription factor Hif-1α, which plays an important role in
angiogenesis, was measured by Western Blot.
4.2.8.1. Protein Extraction
Cells were seeded in 48-well plates with a density of 2 x 105 cells per well and treated
with temozolomide after an attachment time of 24 h. After 1 h cobalt(II) chloride with
a final concentration of 250 µM was added and incubated for 3 h to enhance basal Hif-1α
production. Plates were put on ice and medium was replaced by 100µl PBS per well.
Content of 8 wells with the same condition was scratched off with a Cell scraper and
transferred into a 1.5ml tube. Centrifugation at 4000 rpm at 4 °C was performed for
3min and supernatant was discarded. The pellet was resuspended in 20µl of 99% RIPA
buffer and 1% Protein Inhibitor Cocktail solution. Proteins were extracted by passing
the cell suspension several times through a narrow needle and thereby breaking up the
cell membranes. The tubes were stored at -20 °C until further usage.
4.2.8.2. SDS-PAGE
A polyacrylamide gel electrophoresis was performed in order to separate the proteins
by molecular weight. First, a resolving gel was produced and filled between two glass
plates, which were hold together by a gel caster. Second, the stacking gel was filled on
top of the polymerized resolving gel and a comb was placed in it to preform the slots for
the samples. Ingredients of the stacking gel and the resolving gel are shown in table 4.6.
After 20min the glass plates with the gel were wrapped in plastic foil and stored at 4 °C
until the next day. The gel was then put into an electrophoresis chamber which was filled
with Running buffer. Samples were thawed, homogenized by passing through a narrow
needle and centrifuged with 13,200 rpm at 4 °C for 4min and 20 µl of the supernatant
was mixed with 8µl of Loading buffer. After a heating period at 95 °C for 7.5min the
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Stacking gel Resolving gel
2.1ml Water 4ml Water
0.38ml 1.5M Tris (pH 6.8) 2.5ml 1.5M Tris (pH 6.8)
0.03ml SDS 10% 0.1ml SDS 10%
0.5ml Acrylamide mixture 3.3ml Acrylamide mixture
0.03ml Ammonium persulfate 10% 0.1ml Ammonium persulfate 10%
0.003ml TEMED 0.004ml TEMED
Table 4.6. Ingredients for SDS-PAGE
samples were loaded in the slots of the gel. One slot was filled with 7µl of a 1 kb marker
to observe the progress of the protein bands and later on to determine the molecular
weight of the labeled proteins. The gel was now set under an electric field. Due to the
building of negatively charged micelles caused by SDS, the proteins migrated towards
the anode. Under a constant voltage of 70V the proteins passed through the large pores
of the stacking gel within 15min. The voltage was then switched to 120V and ran for
2 h. The dense matrix of the resolving gel allowed smaller proteins to run faster, while
bigger proteins were slower. In that way a separation according to molecular weight was
achieved.
4.2.8.3. Membrane Transfer
For the transfer of the proteins from the SDS gel onto a nitrocellulose membrane the
gel was cut into the right size and placed in a cassette between filter paper and the
membrane. To avoid drying of the gel, the filter paper, the nitrocellulose membrane and
the gel itself were immersed in transfer buffer. Bubbles between the different layers were
removed by a roller. The cassette was closed, placed into an electrophoresis chamber
and orientated in a way that the gel was facing towards the negative pole while the
nitrocellulose membrane faced the positive pole. An electrical voltage of 55V was applied
for 2 h and the gel was permanently cooled by a block of ice. Meanwhile the negatively
charged proteins could move towards the anode and bind to the membrane.
4.2.8.4. Detection and Analysis
The following steps were performed on a shaker. After blotting the sample proteins to
the membrane, the efficacy of the transfer was verified with a Ponceau dye which colored
the protein bands red. Before and after this step, the membrane was washed 3 times
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with TBST. Then the membrane was saturated with 2.5% milk in TBST solution for
1 h at room temperature. This was necessary to prevent unspecific antibody binding.
The membrane was incubated overnight at 4 °C with Hif-1α antibody which was diluted
in 5% milk solution. Through the previous blocking process all binding sites were oc-
cupied with either sample or milk protein and the detection antibody could therefore
exclusively bind to the sample protein. At the next day the membrane was rinsed three
times with TBST for 5min and incubated for 1.5 h with the secondary antibody. The
secondary antibody was directed against the Fc part of mouse antibodies and was linked
to a horseradish peroxidase enzyme at its own Fc part. The membrane was washed
three times with TBST for 5min to remove redundant antibody. Afterwards it was put
into a plastic foil and incubated for 1min in the dark with ECL detection reagent. The
horseradish peroxidase interaction with the ECL substrate results in enhanced chemi-
luminescence. The membrane was transferred into a hypercassette and covered with
an autoradiography film in a darkroom. The incubation time was varied to achieve
an optimal contrast range. The autoradiography film was taken out and immersed in
developer solution, rinsed with water and with fixer solution. Wherever the sample
protein bound with the antibodies and the horseradish peroxidase was attached to the
membrane, chemiluminescence was detected by the autoradiography film. In order to
relate the received bands to the total protein amount, another detection process was
performed with a ß-actin antibody as primary antibody. ß-actin is a structure protein,
which is present in all eukaryotic cells. To perform this detection, the membrane first
had to be deliberated of the bound antibodies. Therefore it was washed 1min with
water followed by 30min incubation with stripping solution, another washing step with
water and another 30min of stripping. After another blocking step, the procedure was
the same as done with the Hif-1α antibody. The autoradiography films were sticked on
a white paper and scanned as a tif file. The bands were analyzed with Image J.
4.2.9. Statistical Data Analysis
Quadruplicate wells were used for the individual experiments. Each experiment was
repeated thrice. Data were analyzed with one way analysis of variance, followed by post
hoc analysis using the Bonferroni method. A p value of <0,05 was considered significant
and marked with an asterisk.
41
5. Results
5.1. Influence of Temozolomide on Proliferation
An antiproliferative effect on pituitary tumor cells was postulated based on previous
experiments with temozolomide, but only sparse in vitro data exists so far. In this study
different methods were used to assess the influence of temozolomide on proliferation
and metabolic activity of pituitary cells in cell culture. For the experiments we used
rodent pituitary cells lines (GH3 and AtT-20) and human pituitary adenomas in primary
culture. Additionally, some experiments were performed using primary culture of rat
pituitaries in order to obtain information on how temozolomide acts on healthy pituitary
cells.
5.1.1. Direct Cell Counting
For the GH3 cell line, a dose dependent reduction of the cell number was observed as
measured by the Scepter® tool (see figure 5.1). The effect was more prominent after
4 hours than after 24 and 48 hours. After 4 hours the number of cells stimulated with
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Figure 5.1. Cell count of cell lines
Cells were stimulated with different concentrations of temozolomide. The number of cells per well
was measured with the Scepter® tool after 4, 24 and 48 hours. Columns indicate the number of cells
in percentage of control. Results for AtT-20 cells are shown in a). Results for GH3 cells are shown
in b).
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100 µM temozolomide was reduced to 42% [±8%], after 24 hours the reduction accounted
for 77% [±10%] and after 48 hours the cell number was reduced to 72% [±5%]. In the
AtT-20 cell line, after an initial dose dependent increase in cell number to 133% [±8%]l
after 4 hours of stimulation with 100µM temozolomide, a strong decrease to 60% [±10%]
was evident after 48 hours.
5.1.2. 3H-thymidine Incorporation
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Figure 5.2. 3H-thymidine incorporation in cell lines and tumors
Cells were stimulated with different concentrations of temozolomide. 3H-thymidine was added for
24 hours to the adenoma cells and for 4 hours to the cell lines. After the respective time points,
radioactivity was measured in a scintillation counter. Results are shown for AtT-20 (left) and GH3
cells (right) in a). Incorporation rates of different pituitary tumors are shown in b) and each column
represents 3H-thymidine incorporation at 100μm temozolomide from one tumor.
Figure 5.2 shows the temozolomide induced changes in 3H-thymidine incorporation in
the rodent pituitary cell lines. In the GH3 cell line, 3H-thymidine incorporation was
dose-dependently increased to 174% [±27%] of control after 96 hours [p<0,001]. The
increased incorporation was evident throughout all 4 days of treatment. For all tested
temozolomide concentrations, no time-dependent trend was observed since levels of 3H-
thymidine incorporation remain constant of time. In contrast to GH3 cells, a time
dependent change was observed for AtT-20 cells. While the incorporation was strongly
increased to over 300% of control after 24 hours [p<0,001], this trend was inverted in
the following days. After 24 hours of temozolomide treatment, the incorporation rates
in all measured temozolomide concentrations are reduced to the level of incorporation
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observed for the control. Strikingly after three and four days of temozolomide treatment
a clear dose-dependent trend towards a strong reduction of 3H-thymidine incorporation
was observed [p<0,001]. After four days of temozolomide treatment a maximal reduction
to 17% with 100 µM temozolomide was evident in the AtT-20 cell line.
Alongside the measurements in the cell lines, 3H-thymidine incorporation of different
human pituitary adenomas after 24 hours treatment with 100 µM temozolomide was also
determined. Investigation of longer incubation time periods showed a time-independent
response regarding 3H-thymidine incorporation and therefore no significant changes com-
pared to 24 hours of treatment were observed (data not shown). Due to the limited
amount of material, a standard incubation period of 24 hours was chosen. Changes of
3H-thymidine incorporation after 24 hours in the human adenomas are also shown in
figure 5.2c. Only cells of one adenoma showed a clearly visible, but not significant reduc-
tion of 3H-thymidine incorporation [p=0,079]. In contrast, an increased incorporation
of 3H-thymidine (more than 10% compared to control) was observed for eight tumors.
Two tumors showed a highly increased incorporation that doubled the incorporation
rate of the control. However, the majority of adenomas (15 of 17) showed no significant
change in 3H-thymidine incorporation, similar to the observations made with the GH3
cells. There was no significant difference between the secretion types of the investigated
adenomas [p=0,613].
5.1.3. Colony Formation Assay
The number of colonies formed after temozolomide treatment was strongly reduced in
both cell lines (see figure 5.3). In the AtT-20 cell line, the number of colonies was reduced
to 57% [±17%] after one and to 28% [±14%] after two weeks of treatment with 100 µM
temozolomide. A significant reduction of colony number was already present with 25µM
temozolomide. It should be noted that no changes in colony size were induced by temo-
zolomide (see figure 5.4). Colonies of GH3 cells were reduced to 57% [±6%] after one
and to 43% [±22%] after two weeks treatment with 100 µM temozolomide. No significant
reduction of colony formation of GH3 cells was observed for low temozolomide concen-
trations, indicating that the cells were less sensitive towards temozolomide treatment
compared to the AtT-20 cells. In agreement with the findings for GH3 cells, no changes
were observed regarding colony size after temozolomide treatment.
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5.2. Influence of Temozolomide on Hormone Production
The influence of temozolomide on the production of hormones of cells from the AtT-20
and GH3 cell lines and cells from primary culture of human adenomas and pituitaries of
healthy rats was investigated using radioimmunoassays.
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Figure 5.3. Colony formation in pituitary cell lines
Cells were seeded out in 6-well plates with low density and stimulated with different concentrations
of temozolomide. After the respective time periods, colonies were stained and dried. The plates were
scanned and analyzed with the Clono program [170]. a) shows the number of AtT-20 cell colonies in
% of control after 1 week of attachment followed by 1 week of temozolomide stimulation. b) shows
the number of AtT-20 cell colonies in % of control after 1 day of attachment followed by 2 weeks of
temozolomide stimulation. c) shows the number of GH3 cell colonies in % of control after 1 week
of attachment followed by 1 week of temozolomide stimulation. d) shows the number of GH3 cell
colonies in % of control after 1 day of attachment followed by 2 weeks of temozolomide stimulation.
Control 5µM TMZ 25µM TMZ 50µM TMZ 100µM TMZ
Figure 5.4. Colony formation in AtT-20 cells
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5.2.1. Effects on Cell Lines
The cell number of each well was measured with the Scepter® while hormone production
was determined by radioimmunoassay and normalized to the number of cells. In total,
there was a decrease in the normalized ACTH production (see figure 5.5). The results
show that after 4 hours of temozolomide treatment, the normalized ACTH production
in AtT-20 cells decreased to 70% of control, whereas after 48 hours the hormone con-
centration was increased to 135% by treatment with 100µM temozolomide compared to
untreated cells. PRL and GH production were investigated in the GH3 cell line. For
both hormones, production per cell was dose-dependently increased after 4 and 24 hours.
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Figure 5.5. Hormone production in pituitary cell lines
a) shows ACTH production per cell number in AtT-20 cells after 4, 24 and 48 hours stimulation with
different concentrations of temozolomide.
b) shows GH production per cell number in GH3 cells after 4 and 24 hours stimulation with different
concentrations of temozolomide.
c) shows PRL production per cell number in GH3 cells after 4 and 24 hours stimulation with different
concentrations of temozolomide.
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5.2.2. Effects on Primary Culture of Rat Pituitary Cells
In primary culture of normal rat pituitaries, ACTH production after 4 as well as 24
hours of treatment was not affected by temozolomide treatment (see figure 5.6). The
same was true when cells were additionally treated with CRH to achieve higher basal
levels of ACTH. Similar results were observed regarding the influence of temozolomide
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Figure 5.6. Hormone production in rat pituitary cells
ACTH production in rat pituitary cells after stimulation with different concentrations of temozolomide
is shown in a). ACTH production after stimulation with different concentrations of temozolomide
and additional corticotropin releasing hormone for enhanced ACTH secretion is shown in b). GH pro-
duction in rat pituitary cells after stimulation with different concentrations of temozolomide is shown
in c). GH production after stimulation with different concentrations of temozolomide and additional
growth hormone releasing hormone for enhanced GH secretion is shown in d). PRL production in rat
pituitary cells after stimulation with different concentrations of temozolomide is shown in e).
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on the production of growth hormone. There was no change in production after 4 or
24 hours temozolomide treatment. No change in hormone production was seen when
cells were additionally stimulated with GHRH to generate higher basal levels of growth
hormone. Comparatively, prolactin production was also not affected by 4 or 24 hours
treatment.
5.2.3. Effects on Primary Culture of Human Adenomas
Production of growth hormone in five acromegalic tumors was not changed by 24 hours
treatment with maximal temozolomide concentrations of 100 µM (see figure 5.7). Ad-
ditional GH-releasing hormone stimulation did not affect the results (data not shown).
ACTH production in a corticotroph adenoma was insignificantly reduced from 177 ng/ml
[±30 ng/ml] in control to 143 ng/ml [±18 ng/ml] with 100µM temozolomide. Similar-
ily in one investigated thyrotroph tumor, TSH levels were reduced from 0,56mlU/l
[±0,2mlU/l] to 0,47ml/U [±0,06mlU/l].
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Figure 5.7. Hormone production in pituitary tumors
Percentual changes in growth hormone production, as measured by radioimmunoassay in human
acromegalic adenomas after stimulation with 100μm temozolomide are shown in a). Each column
represents one somatotroph tumor. b) Changes in ACTH production of one adrenocorticotroph tumor
after stimulation with different concentrations of temozolomide. c) Changes in TSH production of
one thyrotroph tumor after stimulation with different concentrations of temozolomide
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5.3. Influence of Temozolomide on Neovascularization
The influence of temozolomide on the production of two factors involved in the process
of angiogenesis, Hif-1α and VEGF, was examined using ELISA and Western Blot. Mea-
surements were performed in primary culture of human pituitary adenomas. Additional
treatment with CoCl2 was performed in order to mimic hypoxic conditions, since under
hypoxic conditions, a higher basal VEGF and Hif-1α production is measured.
5.3.1. Influence on VEGF-production
VEGF-production was assessed using specific ELISA in 11 pituitary adenomas in the
presence and absence of a simultaneous CoCl2 stimulation, which increases basal VEGF
production levels (see figures 5.8a) and 5.8b, respectively). With CoCl2 stimulation, the
decrease after 100µM temozolomide treatment was 13% [±8,6%]. The inhibitory effect
was also apparent in cells of five adenomas that were not treated with CoCl2 (reduced
VEGF production of 13% [±6,1%]). Yet, the observed inhibition in both experiments
was not significant. The tumors used in these experiments included non-functioning or
somatotroph adenomas. However, no difference between the types of tumors with regard
to VEGF production was observed (compare figure 5.8).
5.3.2. Influence on Hif-1α Production
Production of Hif-1α by 7 human pituitary adenomas (6 non-functioning and 1 soma-
totroph) was determined using western blots. In order to achieve higher basal levels of
Hif-1α, cells were exposed to 125 µM CoCl2. Results were normalized to basal ß-actin
levels as measured by the western blot. The effects of temozolomide treatment between
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Figure 5.8. VEGF production in pituitary tumors
VEGF was measured by ELISA after 24 hours of stimulation with temozolomide. Columns in a) show
VEGF production in pituitary tumors after stimulation with 100μm temozolomide and additional
CoCl2 treatment. Columns in b) show VEGF production in pituitary tumors after stimulation with
100μm temozolomide.
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adenomas ranged from strong enhancement in two tumors to strong depression of Hif-
1α production in one tumor (see figure 5.9). Each experiment was performed using
temozolomide doses ranging from 5 to 100µM, but no dose dependency was observed.
0%
50%
100%
150%
200%
250%
Hif-1α
[% of control]
Pituitary tumors
a) b)
anti ß-actin
anti Hif1-α
TMZ (µM)
CoCl2 + + + + +
5 25 50 100
-
- -
Somatotroph tumors NFPA
Figure 5.9. Hif-1α production in pituitary tumors
Hif-1α expression levels were measured using western blotting. a) Exemplary western blotting result of
one tumor. Bands for ß-actin and Hif-1α are shown. CoCl2 treatment and temozolomide treatment are
indicated. b) Each column represents Hif-1α production after stimulation with 100μm temozolomide
in one tumor.
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The goal of this study is the in vitro characterization of temozolomide regarding its
effect on cell proliferation and hormon production. In this chapter, the limitations of
the methods will be discussed and finally the results of the in vitro experiments will be
discussed. The chapter finishes with an outlook and a summary.
6.1. Discussion of Methods
Some limitations of the methods used in this study trace back to uncertainties and
missing knowledge regarding the adenoma samples obtained from patients after the
surgery. The classification of the used human pituitary adenomas into subtypes was
performed by the operating surgeon. Criteria used for the classification were therefore
excessive hormone secretion and clinical features that proposed the classification to a
certain adenoma subtype. Data of the immunohistological identification of the tumor
type were not obtained, because there was not enough material left for a histopathological
classification. We assume, that the pre-surgical laboratory investigations of the patients
from which the pituitary tissue in this study was obtained, included an evaluation of all
pituitary hormones as recommended by the WHO guidelines [172].
Moreover no differentiation between tumors that had received prior treatment and
those that hadn’t been treated at all was done in this study. Consequently, no distinction
was made between the types of pretreatment.
The tumors that were obtained from the surgeons mainly include those tumors that
could not be controlled medically and therefore needed surgical removal. As a result, the
set of tumors used in this study is biased towards more aggressive pituitary tumors. This
fact is however reflecting clinical reality as temozolomide is only applicable for those tu-
mors failing conventional medical treatment or surgery. The results consequently do not
represent an overview about all types of pituitary adenomas, but only about those failing
medical treatment or requiring surgery for any other reason. As a consequence, the inves-
tigated adenomas included mainly non-funtioning pituitary adenomas and somatotroph
tumors. Lactotroph or gonadotroph tumors could not be obtained for preparation.
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Another potential bias lies within the acquisition of the tumors. Although the viabil-
ity of the tumor cells was verified for every obained sample, it remains unknown how
resection, transport and processing steps required for cell culture have influenced the
tumors response to the chemotherapeutic agent. In order to achieve a better picture
of the in vivo situation, experiments using different pituitary cell types were combined.
The murine pituitary cell lines serve as a model for the fast growing pituitary tumors
and have the advantages to be easy to handle and to generate reproducible results. The
constant cultivation however might lead to different results than would be obtained re-
garding the original tumor cells. In order to compensate for this effect, we also used
cells in primary culture.
Other limitations of the study arise from the in vitro design: of course, the results
obtained from cell culture studies cannot be translated into the in vivo situation without
critical assessment. Additional aspects must be considered in the complex body. In vivo
it has been shown, that temozolomide reduces tumor mass and has an inhibitory effect
on angiogenesis, which might add to the observed good clinical outcome [173]. Besides
that, temozolomide has been shown to cause local hemorrhage, fibrosis and necrosis
[151, 174, 175]. While measuring effects on cell proliferation in vitro is easily achieved,
measuring effects on angiogenesis is more difficult. Angiogenesis and the supply of
oxygen is not a limiting factor for the growth of single cells in cell culture, but it is
essential for tumor cells growing in tissue. The measurement of a single factor involved
in angiogenesis was used in this study as a read-out for effects on angiogenesis, but it
should be noted that it is only a single component of the complex system of angiogenesis.
More factors need to be taken into account to achieve a more accurate picture.
Previous in vitro studies that showed a strong effect of temozolomide in GH3 and AtT-
20 cells such as Dai et al.[149] used a concentration of 250µM TMZ to stimulate cells. In
this study, a maximum dose of 100 µMTMZ was chosen to more accurately reflect plasma
and intratumour concentrations that have been determined in previous clinical trials. In
the conventional schedule with a daily dose of 200mg/m2 TMZ, plasma concentrations
range from 0,1 to 16 µg/mL, corresponding to doses of 0,5 to 82 µM TMZ. Accumulation
over the treatment period of 5 days has not been observed [176, 177, 178, 93]. In
this study, temozolomide concentrations range from 5 to 100 µM and therefore perfectly
mimic the temozolomide concentrations found in vivo.
As a measure of cell proliferation, the 3H-thymidine incorporation method is often
used in cell culture. 3H-thymidine incorporation and clonogenic assays have been shown
to highly correlate with clinical outcome [179]. In this study, the mechanism of action
of temozolomide generates increased mononucleotide uptake before inducing apoptosis
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in the cell. Therefore, an initial increase in 3H-thymidine incorporation was expected.
After all, for a direct measurement of proliferation, the 3H-thymidine incorporation could
not be used as solely method, because a decrease in incorporation could either be the
effect of a reduction in cell number, or a decrease in metabolic activity of a greater
cell number. Hence, the study was extended to complementary methods that measure
cell proliferation: Direct cell counting with the Scepter® and a clonogenic assay. As
suggested by Hueng et al. the measured total hormonal production was normalized to
the number of cells allowing to evaluate a specific effect on hormone production [180].
To this end, the data obtained with the Scepter® tool were used, because it is a fast and
accurate method of determining cell numbers [181].
Clonogenic assays are used to provide information on how the drug influences the
capacity of the cells to build colonies and their capacity to proliferate. It was shown that
the capacity of colony formation influences the in vivo capacity of the tumor to develop
micrometastases. The colony formation assay that we used had a simple, monolayer
design. Obviously this is just a model and allows no definite conclusions for the transfer
to the in vivo situation. It provides only two-dimensional cell to cell contacts and does
not acclaim for the multiple other factors involved for the formation of a metastasis
in vivo [182]. Noticeably in a study where single layer culture methods and three-
dimensional spheroid models were compared, alkylating drugs showed no difference in
toxicity [183]. A possible methodical flaw of this assay is the erroneous confusion of cell
clumps and cell colonies during the counting process.
Neovascularization is an important mechanism for tumors to acquire access to nu-
trients and oxygen, which is needed for tumor growth. VEGF has been shown to be
one of the most important factors in angiogenesis. For measuring a possible effect of
temozolomide on neovascularization, we measured VEGF expression in human pituitary
adenomas with or without additional treatment with CoCl2. CoCl2 has been shown to
closely mimic hypoxic conditions and is therefore used in our experiments as a model
for hypoxia [184]. To create a better picture of the effects on neovascularization, we also
evaluated the production of Hif-1α. Hif-1 is a transcription factor that is responsible for
the regulation of multiple important genes for a cellular adaption to hypoxic stress. It
is constitutively expressed and degraded under normoxic conditions. In hypoxia, degra-
dation is prevented by a redox-dependent pathway [185].
53
6. Discussion
6.2. Results in the Context Of Literature
6.2.1. Temozolomide Inhibits Proliferation and Clonogenic Potential of
Pituitary Cells
Evaluating the effects on proliferation of the tumoral pituitary cells was one of the main
goals of this thesis. In this study, proliferation was measured by direct cell counting,
a clonogenic assay and 3H-thymidin incorporation. These experiments were conducted
with murine pituitary cell lines and murine and human pituitary cells in primary culture.
The direct cell counts of the pituitary cell lines showed a significant reduction after
temozolomide treatment. The AtT-20 cells were reduced to 60% after 48 hours and the
GH3 cell number was reduced to 72%. The reduction in proliferation that we observed
in the pituitary cell lines are in agreement with the study of Sheehan et al. [167] and Ma
et al.[168] who already demonstrated suppression of growth in the MMQ, GH, AtT-20
and αT3-1 pituitary cell lines.
In the clonogenic assay we showed for the first time that temozolomide could effectively
suppress the clonogenic potential of pituitary cells. Both, the AtT-20 and the GH3 cell
line demonstrated a markedly decreased number of cell colonies. Moreover temozolomide
has already been shown to reduce the metastatic potential in cells of several derivations
[186].
The results of the 3H-thymidine assay show that incorporation of labeled thymidine in
AtT-20 cells has two phases: first, a dose-dependent increase after 24 hours and secondly
a strong reduction after 72 and 96 hours. A possible explanation for this observation
lies within the mechanism of temozolomide function. As already mentioned previously,
the O6 methylated guanine mispairs with thymine, therefore leading to activation of
mismatch repair which in turn leads to increased thymidine incorporation. After the
cells died from the cytotoxic effects of temozolomide, incorporation decreases as observed
for long incorporation times. Interestingly, the GH3 cells showed a constant increase in
3H-thymidine incorporation, though direct cell counting revealed a reduction in cell
number. This can be explained by a strongly increased 3H-thymidine incorporation.
However, levels of the corresponding proteins MGMT or MSH6 wer not determined in
this study. Sheehan et al. observed a similar dynamic using the MTT assay, an assay
that assesses metabolic activity to determine cell viability. GH3 cells first showed good
response to temozolomide, but then seemed to recover. We assume that the GH3 cells are
less sensitive to temozolomide than the AtT-20 cells. By whatsoever mechanism, they
show upregulated DNA synthesis in the remaining cells. Understanding the underlying
mechanism should be the goal of future studies.
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The human pituitary adenomas that we investigated showed mostly no change in 3H-
thymidine incorporation. Only one tumor showed a strong, but not significant reduction
of incorporation. Instead, eight tumors demonstrated increased incorporation. These
results do not correspond to the observations reported in the literature. A possible reason
might be the same effect that we already observed with the GH3 cells: 3H-thymidine
incorporation might not have been an accurate method to determine changes in cell
viability or proliferation induced specifically by temozolomide because of its interference
with the mechanism of action of temozolomide. Other metabolism based assays would
have been more appropriate for this purpose.
In general, the primary culture cells that we investigated seemed to be less responsive
to temozolomide compared to the pituitary cell lines. This is a common phenomenon,
because cell lines have a higher proliferative index and are assumed to mimic the sit-
uation in an aggressive tumor. The primary cells thus have low growth rates and less
metabolism. In the literature that is summarized in appendix A, the effect of temo-
zolomide in pituitary tumors creates a mixed picture, with 58% of the treated patients
responding. In some patients large and quick reductions in hormone levels and tumor
size were observed while for other patients a slow but steady decline of hormone levels
was observed. But still, there are many patients who either did not show any response
or suffered from recurrences. This heterogeneous situation resembles the observations
in cell culture that we investigated. These differences strongly suggest the presence of
mechanisms of resistance that remain to be unvealed.
6.2.2. Temozolomide Reduces Hormone Levels Through Reduction of Cell
Number
In the treatment of patients with pituitary neoplasms, it is not just important to know
whether the treatment has an effect on the tumor itself, but also how it affects the
surrounding healthy pituitary tissue. While radiotherapy and surgery leave patients
with a high rate of hypopituitarism, this does not occur under medical treatment with
dopamine agonists or somatostatin analogues. Our results in primary culture indicate
that there is no effect on secretion of ACTH, PRL and GH of normal, healthy rat
pituitary cells. We investigated this with and without additional stimulation with CRH
and GHRH in the case of ACTH and GH measurements. These results are in agreement
with the observations gathered from the clinical experience with temozolomide. Regular
measurements of pituitary hormone levels in patients treated with temozolomide gave
no indications of a temozolomide induced hypopituitarism. Nevertheless, a previous
study based on five cases suggested temozolomide to potentially cause central diabetes
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insipidus [163]. However, it remains unknown whether diabetes insipidus was caused by
a temozolomide induced change of ADH production, secretion or storage. Considering
the large number of patients treated with temozolomide and the low number of reported
cases of diabetes insipidus, the development of this side effect seems to be a rare event.
Further studies and longer experience with the use of the drug will reveal a possible
connection between central diabetes insipidus and temozolomide use.
Oversecretion of pituitary hormones is one of the most important harms caused by
pituitary tumors. Dopamine agonists and somatostatin analogues are successfully used
to reduce hormonal excess in the majority of patients. However, some patients never show
any response or develop resistance throughout the therapy. In the case reports listed in
appendix A, a temozolomide induced reduction in hormone secretion was observed in
79% of the prolactin secreting tumors, in 81% of the corticotroph tumors and in 50% of
the growth hormone secreting tumors. The single gonadotroph tumor that was reported
in the literature showed no reduction in hormone secretion. Apart from that we found no
case, where temozolomide had been used in a thytotrop tumor. The correlation between
a positive radiological response and a biochemical decrease in hormones is very high.
All of the tumors, where a reduction in hormone secretion is mentioned also show a
radiological response. So far, there is only one case report, where a noticeable drop in
hormone levels was not accompanied by a reduction in tumor size [187].
In our experiments we found no change in growth hormone production in the case
of five somatotroph adenomas as well as slight, but not significant reductions of ACTH
in one corticotroph and of TSH in one thyrotroph adenoma after treatment with a
maximum dose of 100µM TMZ. Unfortunately, no prolactin producing adenoma could
be acquired. In comparison with the clinical experience that has already been made
with temozolomide, this in vitro response rate seems to be low. A possible reason might
be the low growth and metabolic rate of human pituitary adenomas in primary cell
culture. To account for this effect, we provided additional stimulation of basal hormone
secretion via GHRH and CRH, which enhanced basal secretion, but had no effect on
temozolomide response. Finally, when considering the missing effect on proliferation of
human pituitary adenomas seen in the 3H-thymidine incorporation experiment and the
lack of a specific hormone reducing effect as seen in the cell lines, these results contribute
to the hypothesis, that there is no specific hormone suppressive effect of temozolomide.
Pituitary cell lines are used as a model for fast growing pituitary tumors. A hormone
suppressive effect on pituitary cell lines has already been demonstrated by Sheehan et
al. and Ma et al. The Ma group demonstrated the reduction of FSH and LH production
in the gonadotroph αT3-1 cell line while Sheehan et al. already demonstrated a temo-
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zolomide induced reduction in PRL secretion in the pituitary GH3 and MMQ cell lines.
[167, 168]. In both studies non-physiological temozolomide concentrations were used
and only total hormon secretion was measured. In order to reveal the specific effects
on hormone secretion, we measured hormone production per cell. In the corticotroph
AtT-20 cells, no significant change in ACTH production per cell was observed. The
GH3 cell line showed no change on PRL production per cell but a slight increase in GH
production per cell.
The findings suggest that a reduction of hormone secretion might rather be due to a
reduction in cell number, than to a specific hormone suppressive effect on a cellular level.
The considerable reductions in hormone levels that were found by Ma et al could therefore
be explained by the deleterious effect on cell viability. Consequently in cases where tumor
growth under temozolomide treatment is observed, a change of drug seems warranted as
the mechanism of action of temozolomide induced effects on hormone secretion seem to
be obtained by tumor shrinkage and not via specific inhibition of hormone secretion.
6.2.3. Temozolomide Inhibits Neovascularization
Neovascularization is a necessary step in tumorigenesis for gaining access to nutrients
and oxygen and for the removal of unneeded metabolic products. Most human tumors
exhibit an increased rate of angiogenesis compared to normal tissue. Pituitary tumors
appear to be different. In a study consisting of 157 pituitary adenomas and 7 carcinomas,
microvessel density as a parameter of angiogenesis was investigated. A small, but not
significant correlation between microvessel density and invasiveness of the tumor was
found. Microvessel density was higher in the investigated pituitary carcinomas in this
study, but not in another study. In general pituitary adenomas seem to have a lower
microvessel density than healthy pituitary tissue, which is supposed to result in the
comparatively slow pace of pituitary tumor growth [188, 189].
A similar observation is made regarding VEGF expression of pituitary adenomas.
VEGF is the most important signal protein involved in the formation of new blood
vessels and recent findings even suppose a role in regulating growth of pituitary adenomas
[190]. In benign pituitary adenomas, VEGF expression seems to be lower than in healthy
pituitary tissue, but pituitary carcinomas have been shown to have upregulated VEGF
expression compared to pituitary adenomas [191]. This is in agreement with the positive
correlation between metastasizing and neovascularization that has been demonstrated for
many other tumor types [192]. Discordant results were reported regarding the connection
between pituitary tumor invasiveness, VEGF expression and microvessel density, partly
due to methodological differences [193]. It is not yet known whether the low microvessel
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density of pituitary adenomas is due to their low growth rate, an ingrowth of vessels of
the pituitary gland or an inhibition of angiogenic factors. In spite of the inconsistent
results in the literature, a VEGF reducing effect could be beneficial in case that future
studies would reveal a definite link to tumor aggressiveness. A recent study using a mouse
model of dopamine resistant prolactinomas showed that inhibition of VEGF resulted in
a decrease of tumor size and reduction of prolactin content. Therapeutic targeting of
VEGF therefore seems warranted in dopamine resistant prolactinomas [194].
By measuring VEGF and Hif-1α production of the temozolomide treated cells, we
wanted to extend the current knowledge on how temozolomide influences angiogenesis.
We compared basal to temozolomide induced changes in VEGF expression of human pi-
tuitary adenomas under normoxic and hypoxia-like conditions in primary culture. When
cells were treated with a final dose of 100µM temozolomide, a small, not significant re-
duction of 13% VEGF levels was apparent in five investigated adenomas. The same was
true under hypoxia-like conditions that were induced by CoCl2 treatment of the cells. A
13% reduction of VEGF levels of 11 human pituitary adenomas was generated by 100µM
temozolomide. These results indicate that there could be a small anti-angiogenic effect
of temozolomide on pituitary adenomas. Restrictions must be made due to the small
sample size and the fact that we examined mostly NFPA. Effects might be different
among the adenoma types, but we did not have enough material to examine poten-
tial differences. Basal levels of VEGF protein expression and microvessel density have
though been shown to differ among the adenoma types with growth hormone producing
tumors having the lowest levels [189].
Hif-1 is a modulator of angiogenesis and promotes transcription of a large quantity of
genes in response to hypoxic conditions, including VEGF. Hif-1 consists of two dimers,
the α subunit which is oxygen and growth hormone regulated and the β subunit, which
is constitutively expressed [195, 196]. We could not detect an effect of temozolomide on
Hif-1α production in 7 human pituitary adenomas. The results varied greatly among
the investigated tumors: Hif-1α production was strongly enhanced in two tumors and
strongly suppressed in one tumor while no effect was observed in the remaining four
tumors. However, since the sample size was very small, this complex respond pattern
cannot be examined in detail. The great variation of Hif-1α levels could be explained
by differences in temozolomide sensitivity or it might just have been a methodological
problem. We did not assess the MGMT status of the investigated adenomas in order to
correlate the findings. A greater sample size could maybe reveal if there is an effect of
temozolomide on Hif-1α production or degradation. Earlier studies have shown the Hif-1
dependent VEGF production in common tumor angiogenesis, but Kim et al. found no
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relation between Hif-1 and VEGF expression in a series of human pituitary adenomas
[197, 198]. So far there have been no other studies investigating anti-angiogenic effects
of temozolomide in pituitary cells, but reduction of microvessel density as well as Hif-1
and VEGF production by temozolomide have already been demonstrated in glioma cells
[173, 199]. Likewise, angiogenesis of chicken chorioallantoic membranes was inhibited
by temozolomide, namely by low, non-toxic concentrations of temozolomide [200]. Re-
garding the toxicity of temozolomide, angiogenesis does not seem to be a major factor,
because the vascularization in pituitary adenomas is low in general. Nevertheless we
could show a small VEGF-suppressive effect which might at least add up to the efficacy
of temozolomide in the treatment of pituitary adenomas.
6.3. Outlooks
Temozolomide treatment is the last line treatment option for patients with aggressive
pituitary adenomas and pituitary carcinomas. Although the observed response rate of
58% is quite high, there is still a large number of patients that do not benefit from temo-
zolomide treatment. For these patients no clinically approved treatment options exist
so far. Efforts have been made to identify new drugs that are effective in the treatment
of resistant tumors. Studies on the mTOR inhibitors everolimus and rapamycin have
demonstrated in vitro effectiveness in pituitary cell lines and primary culture of pitu-
itary adenomas, especially in the combination with the somatostatin analogue octreotide
[201, 202, 203]. However, a clinical application of an everolimus and octreotide combina-
tion in a patient with an ACTH producing pituitary carcinoma showed no success [204].
Nevertheless further trials with patients that do not respond to temozolomide treatment
seem warranted, as laboratory results seem promising and other alternatives are rare.
Another option to receive higher response rates could be the combination of temozolo-
mide and other drugs. Capecitabine, MGMT-inhibitors, PARP-inhibitors, pyrimethamine
or antiangiogenic agents all have been used together with temozolomide in vitro or in
vivo, but there is still insufficient data for a broad application of these combined treat-
ments [142, 149, 147]. However, it must be ensured that the combination of two agents
does not increase systemic toxicity or is potentially mutagenic.
New treatment regimens might also enhance temozolomide effectiveness. For glioblas-
tomas, temozolomide has been shown to increase the sensitivity for radiation [205, 206].
This resulted in the remarkable improvement of survival rates from 10.4% for pa-
tients treated with radiation only to 26,5% treated with radiotherapy and concomi-
tant temozolomide [135]. Studies in pituitary tumors investigating simultaneous radio-
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chemotherapy and in vitro studies regarding a possible radio-sensitizing effect of temo-
zolomide in pituitary cells remain to be done. Another possible strategy to improve
treatment effectiveness is the initiation of temozolomide treatment before radiotherapy,
a so called neoadjuvant approach. In patients suffering from glioblastoma, neoadjuvant
treatment with temozolomide has already proven effective, but also in this case, studies
in pituitary tumors haven’t been performed yet [207, 208].
Besides from adding new drugs or radiation to the current treatment, variations
of therapeutic schedules provide promising alternatives compared to the conventional
temozolomide treatment of a 200mg/m2 daily dose during five-days every four weeks
[209, 210]. Most regimens use lower doses of temozolomide for a longer time period, as
laboratory findings suggested better efficacy without an increase in toxicity. However,
some schedules have proven ineffective if compared with the conventional schedule [211].
One more point that still needs to be addressed is the optimal length of treatment. The
experience with temozolomide has so far shown that on the one side, there are patients
that develop recurrent disease after cessation of temozolomide [187], on the other side
there are some patients that acquire temozolomide resistance, possibly due to selective
pressure on the cells [123, 122]. A rationale for the optimal individual length of treatment
still needs to be found.
Right now, temozolomide is only used in cases, where other treatment options already
failed. Due to the low rate of side effects, it seems warranted to discuss the initiation
of temozolomide at an earlier point of time. Therefore early identification of malignant
tumors must be accomplished. First attempts to achieve better prognostic markers for
malignant transformation or recurrence rate have already been suggested. A high Ki-67
index correlates with recurrency and therefore warrants close monitoring of MRI and
hormone levels as well as early initiation of additional therapy [212, 213]. In addition
to that, efforts should be made towards the better identification of patients that show
temozolomide resistance. This will primarily be important as soon as alternatives to
temozolomide treatment are found. Unlike in the treatment of glioblastomas, the MGMT
status allows no accurate prediction of response to temozolomide in pituitary tumors.
The MSH-6 status seems a promising marker to identify drug resistant tumors and it
could be a potential target for future research (Compare chapter 2.2.2).
Finally a still futuristic approach might revolutionize antineoplastic therapy: local
delivery of chemotherapeutic drugs through biodegradable polymer wafers is currently
being approved for glioblastomas. A carmustine wafer has already been tested in phase
II studies and showed promising results and a low side effect profile. Devices with temo-
zolomide have already been designed and proved effective in a rodent gliosarcoma model
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[214, 215, 216]. However safe and ready to use temozolomide containing devices still need
to be designed and thoroughly tested before clinical application can be recommended.
In conclusion, based on the response rate of 58% in the published case reports, the
low rate of side effects and the laboratory findings that support the antiproliferative
and anti-angiogenic action of temozolomide, a further use in the following tumors is
warranted: i) dopamine agonist and somatostatin analog resistant prolactinomas and
somatotropinomas that require multiple surgeries and radiotherapy, ii) aggressive cor-
ticotroph, thyrotroph, gonadotroph and non-functioning pituitary adenomas and iii)
pituitary carcinomas.
6.4. Summary
Pituitary adenomas are a common type of tumors with an estimated prevalence of 16.7%
[9]. They present clinically either through excess of hormonal secretion or mass effects.
The therapy of pituitary tumors has four main goals: i) reducing tumor mass, ii) reduc-
ing hormone levels iii), prevent or treat metastases and iv) preserve normal pituitary
function. Usually, the tumors are benign and can be controlled through medication,
radiotherapy or surgery. However, some tumors show locally aggressive behavior or re-
currence to medical or surgical treatment regimens [45]. Until now, no legally approved
treatment options for patients with these types of pituitary adenomas or pituitary car-
cinomas exist so far. Therefore, treatment options need to be urgently identified and
characterized.
Temozolomide was shown to have anti-tumoral effects in several human neoplasms.
Currently it is predominantly used for treating glioblastoma, anaplastic astrocytoma and
malignant melanoma. In this study 103 cases of application of temozolomide in human
pituitary adenoma and carcinoma are listed and summarized in appendix A. Response
rates of temozolomide treatment varied among the investigated patients but with an
average of 58 % responding, it is the best treatment option for this kind of patients.
Patients with aggressive pituitary adenomas or carcinomas that responded to the treat-
ment usually demonstrated tumor shrinkage and a reduction of hormone production
in cases of hormone producing tumors. However the exact effects of temozolomide on
pituitary cells remain poorly understood. To be precise, only two studies in pituitary
cells, suggesting an antiproliferative effects or effects on hormone secretion have been
published[167, 168].
The aim of this study is the investigation of the antiproliferative capacity of temozolo-
mide in different types of pituitary cells and the effects on hormone secretion, neovas-
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cularization and colony formation. In order to get a more precise picture of the effects,
different pituitary cells were used in this study: Healthy rat pituitary cells in primary
culture, human adenoma cells in primary culture as well as rat pituitary cells lines (GH3
and AtT-20 cell line). The set of different cell types was combined with a set of cell-based
assays to determine cell proliferation, including 3H-thymidine incorporation, direct cell
counting and colony formation assays. To probe hormon production biochemical assays
such as Western Blots, radioimmunoassays and ELISA were used.
In this study, proliferation of healthy rat pituitary and most human pituitary adenoma
cells, both obtained from primary culture, were not affected according to 3H-thymidine
incorporation assays. However in the case of rat pituitary cell lines (GH3 and AtT-20
cell line), a reduction of cell proliferation was observed by 3H-thymidine uptake as well
as colony formation assays. The results obtained from cell lines further revealed that the
thymidine incorporation in cells shows a complex time-dependence, which is suggested
to be caused by an interfering increase of DNA repair activity induced by temozolomide
stimulation. As a consequence, the antiproliferative effect of temozolomide was confirmed
with direct cell counting assays for both cell lines.
Hormone measurements in primary culture of human pituitary adenomas showed no
relevant hormone suppressive effects of temozolomide. Regarding healthy pituitary cells,
no relevant effects on GH, ACTH and PRL production of normal rat pituitaries were
found in primary culture. In contrast, the fast growing pituitary cell lines showed a
decrease of the pituitary hormone ACTH. However, hormone production normalized
to the cell number showed no reduction, suggesting that temozolomide has no specific
inhibitory effect on hormone production.
Moreover, Hif-1α and VEGF production after temozolomide treatment was investi-
gated to examine potential effects on neovascularization. VEGF production was slightly
decreased, suggesting a modest inhibitory effect on neovascularization of human pituitary
adenomas. In the case of Hif-1α production no clear trend was observed as temozolomide
can increase or decrease the production in primary culture of human pituitary adenomas.
In this in vitro study, temozolomide was found to be a cytotoxic agent and capable
of reducing the colony forming potential in the case of pituitary cell lines. These effects
might be particular useful in the prevention of cerebral micrometastases deriving from
pituitary carcinomas and therefore, the findings of this study allow to partially under-
stand the previously reported successful application of temozolomide in the treatment of
pituitary adenomas or carcinomas. The results of this study further suggest, that temo-
zolomide solely acts as an antiproliferative agent. This renders temozolomide useful to
reduce tumor size as well as the risk of metastasis, but in terms of hormon secretion of
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pituitary tumors, a reduction is only achieved by reduction of tumor mass, not through
a specific hormone reducing effect.
6.5. Zusammenfassung
Hypophysenadenome sind eine häufig vorkommende, gutartige Tumorart mit einer ge-
schätzten Prävalenz von 16,7% [9]. In der Klinik wird oft eine erhöhte Hormonproduktion
sowie eine Größenzunahme der Hypophysentumore beobachtet. Als Therapieziele gelten
daher i) die Reduktion der Tumorgröße, ii) die Reduktion der Hormonproduktion, iii) die
Vorbeugung oder Behandlung von Metastasen und iv) die Erhaltung der regulären Hy-
pophysenfunktion. Größtenteils sind Hypophysentumore gutartig und können mittels
medikamentöser Therapie, Bestrahlung oder operativer Resektion behandelt werden.
Einige dieser Tumore zeigen jedoch infiltratives Wachstum und sind gegenüber konven-
tionellen Therapiemethoden resistent[45]. Für Patienten, die an dieser Form von aggres-
siven Hypophysenadenomen oder Hypophysenkarzinomen erkrankt sind, gibt es kaum
Behandlungsoptionen. Die Entwicklung neuer Therapiemethoden ist deshalb besonders
wichtig.
Temozolomid hat in der Therapie verschiedener menschlicher Tumorerkrankungen
bereits gute Erfolge erzielt. Es wird derzeit vor allem in der Behandlung von Glioblas-
tomen, anaplastischen Astrozytomen und malignen Melanomen verwendet. In dieser
Arbeit wurden insgesamt 103 publizierte Anwendungsfälle von Patienten gesammelt und
zusammengefasst, die aufgrund eines Hypophysenadenoms oder -karzinoms mit Temo-
zolomid behandelt wurden (siehe Anhang A). Die Ansprechrate der behandelten Patien-
ten liegt bei durchschnittlich 58% und ist somit die momentan beste Therapieoption für
Patienten mit dieser Art von Tumoren. Bei erfolgreichen Behandlungen aggressiver Hy-
pophysenadenome oder Hypophysenkarzinome mit Temozolomid konnte eine Abnahme
des Tumorvolumens sowie bei Hormon produzierenden Tumoren eine Reduktion der
Hormonproduktion beobachtet werden. Die genauen Effekte von Temozolomid auf Hy-
pophysenzellen sind allerdings noch nicht gut erforscht. Tatsächlich existieren lediglich
zwei Studien mit Hypophysenzellen in denen ein antiproliferativer Effekt oder ein Effekt
auf die Hormonsekretion gezeigt wurde[167, 168].
Das Ziel dieser Studie war es die antiproliferativen Fähigkeiten von Temozolomid in
unterschiedlichen Hypophysenzellen zu untersuchen und die Auswirkungen auf Hormon-
sekretion, Neovaskularisation und Koloniebildung näher zu betrachten. Um möglichst
aussagekräftige Ergebnisse über den zellulären Wirkmechanismus zu erhalten wurden
gesunde Rattenhypophysenzellen in Primärkultur, menschliche Adenomzellen in Primär-
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kultur und murine Zelllinien (GH3 und AtT-20 Zelllinien) untersucht. Diese Auswahl
an Zelltypen wurde mit verschiedenen zellbiologischen Experimenten kombiniert, unter
anderem die Quantifizierung des Einbaus an 3H-Thymidin, direkte Messungen der Zell-
zahl sowie der Bestimmung der koloniebildenden Einheiten. Zusätzlich wurden Western
Blots, Radioimmunassays und antikörperbasierte Nachweisverfahren (ELISA) verwendet
um Hormonkonzentrationen zu bestimmen.
In dieser Studie konnte anhand des Einbaus an 3H-Thymidin keine Auswirkung von
Temozolomid auf die Proliferation von gesunden Rattenhypophysenzellen oder men-
schlichen Adenomzellen, jeweils in Primärkultur gehalten, festgestellt werden. Im Falle
der murinen Zelllinien (GH3 und AtT-20 Zelllinien) konnte jedoch mit Hilfe des Ein-
baus an 3H-Thymidin eine Reduzierung der Zellproliferation sowie eine Verringerung der
koloniebildenden Einheiten durch Temozolomid festgestellen werden. Außerdem zeigen
die Daten der Zelllinien, das der Thymidineinbau in Zellen einer komplexen Zeitab-
hängigkeit unterliegt, welche vermutlich von einer interferierenden, von Temozolomid
ausgelösten, erhöhten Aktivität der DNA-Reparatur beeinflusst wird. Daher wurde die
antiproliferative Wirkung von Temozolomid auf die Zelllinien mit direkten Messungen
der Lebendzellzahl bestätigt.
Messungen der Hormonsekretion der menschlichen Adenomzellen in Primärkultur er-
gaben keine hemmende Wirkung von Temozolomid. Auch bei gesunden Rattenhy-
pophysenzellen in Primärkultur blieb die Produktion von GH, ACTH oder PRL nach
einer Stimulierung mit Temozolomid konstant. Im Gegensatz dazu sank im Falle der
schnellwachsenden Zelllinien die produzierte Menge des Hormons ACTH. Allerdings,
blieb auch bei den beiden Zelllinien die auf die Zellzahl normierte Hormonproduktion
konstant, weshalb eine spezifische Hemmung der Hormonproduktion durch Temozolomid
ausgeschlossen werden kann.
Um Rückschlüße auf einen potentiellen Einfluß von Temozolomid auf die Neovaskular-
isierung zu untersuchen, wurde die zelluläre Produktion von Hif-1α and VEGF bestimmt.
Da die VEGF Produktion minimal reduziert wurde, hat Temozolomid vermutlich nur
einen sehr geringen oder keinen Einfluß auf die Neovaskularisierung. Für die Produktion
von Hif-1α konnte in dieser Studie keine Aussage getroffen werden, da sowohl erhöhte
als auch reduzierte Botenstoffkonzentrationen festgestellt wurden.
In dieser in vitro Studie wurde im Falle der murinen Zelllinien eine zytotoxische
Wirkung und eine Hemmung der koloniebildenden Einheiten durch Temozolomid nach-
gewiesen. Diese Wirkungen können vor allem bei der Vorbeugung der zerebralen Metas-
tasenbildung durch Hypophysenkarzinome helfen, weshalb mit den Ergebnissen dieser
Studie die publizierten erfolgreichen Behandlungen von Hypophysenadenomen oder -kar-
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zinomen mit Temozolomid teilweise erklärt werden können. Die Ergebnisse dieser Studie
legen nahe, dass Temozolomid ausschließlich antiproliferativ wirkt. Damit ist Temozolo-
mid geeignet um die Tumorgröße und das Risiko von Metastasen zu reduzieren, eine
Reduzierung der Hormonsekretion wird jedoch nur indirekt über eine reduzierte Tumor-
masse, nicht aber eine spezifische Hemmung der Hormonproduktion erzielt.
65
Bibliography
[1] Nussey, S., and Whitehead, S. (2001) Endocrinology: An Integrated Approach.
[2] Rossoni, E., Feng, J., Tirozzi, B., Brown, D., Leng, G., and Moos, F. (2008)
Emergent synchronous bursting of oxytocin neuronal network. PLoS computational
biology 4, e1000123.
[3] Neumann, I. D. (2008) Brain oxytocin: a key regulator of emotional and social
behaviours in both females and males. Journal of neuroendocrinology 20, 858–865.
[4] Amar, A. P., and Weiss, M. H. (2003) Pituitary anatomy and physiology. Neuro-
surgery clinics of North America 14, 11–23, v.
[5] Melmed, S. (2003) Mechanisms for pituitary tumorigenesis: the plastic pituitary.
The Journal of clinical investigation 112, 1603–1618.
[6] Al-Shraim, M., and Asa, S. L. (2006) The 2004 World Health Organization classi-
fication of pituitary tumors: what is new? Acta neuropathologica 111, 1–7.
[7] Dworakowska, D., and Grossman, A. (2009) The pathophysiology of pituitary ade-
nomas. Best practice & research 23, 525–541.
[8] CBTRUS (2011). CBTRUS Statistical Report: Primary Brain and Central Ner-
vous System Tumors Diagnosed in the United States in 2004-2007.
[9] Ezzat, S., Asa, S., Couldwell, W., Barr, C., Dodge, W., Vance, M., and Mc-
Cutcheon, I. (2004) The prevalence of pituitary adenomas: a systematic review.
Cancer 101, 613–619.
[10] Nilsson, B., Gustavasson-Kadaka, E., Bengtsson, B. A., and Jonsson, B. (2000)
Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and
mortality. The Journal of clinical endocrinology and metabolism 85, 1420–1425.
[11] Billestrup, N., Swanson, L. W., and Vale, W. (1986) Growth hormone-releasing
factor stimulates proliferation of somatotrophs in vitro. Proceedings of the National
Academy of Sciences of the United States of America 83, 6854–6857.
[12] Gertz, B. J., Contreras, L. N., McComb, D. J., Kovacs, K., Tyrrell, J. B., and
Dallman, M. F. (1987) Chronic administration of corticotropin-releasing factor
increases pituitary corticotroph number. Endocrinology 120, 381–388.
66
BIBLIOGRAPHY
[13] Molitch, M. E. (1987) Pathogenesis of pituitary tumors. Endocrinology and
metabolism clinics of North America 16, 503–527.
[14] Herman, V., Fagin, J., Gonsky, R., Kovacs, K., and Melmed, S. (1990) Clonal origin
of pituitary adenomas. The Journal of clinical endocrinology and metabolism 71,
1427–1433.
[15] Morris, D. G., Musat, M., Czirjak, S., Hanzely, Z., Lillington, D. M., Korbonits, M.,
and Grossman, A. B. (2005) Differential gene expression in pituitary adenomas
by oligonucleotide array analysis. European journal of endocrinology / European
Federation of Endocrine Societies 153, 143–151.
[16] Herman, V., Drazin, N. Z., Gonsky, R., and Melmed, S. (1993) Molecular screening
of pituitary adenomas for gene mutations and rearrangements. The Journal of
clinical endocrinology and metabolism 77, 50–55.
[17] Honda, S., Tanaka-Kosugi, C., Yamada, S., Sano, T., Matsumoto, T., Itakura, M.,
and Yoshimoto, K. (2003) Human pituitary adenomas infrequently contain inacti-
vation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene.
Endocrine journal 50, 309–318.
[18] Karga, H. J., Alexander, J. M., Hedley-Whyte, E. T., Klibanski, A., and Jame-
son, J. L. (1992) Ras mutations in human pituitary tumors. The Journal of clinical
endocrinology and metabolism 74, 914–919.
[19] Asa, S. L., and Ezzat, S. (1998) The cytogenesis and pathogenesis of pituitary
adenomas. Endocrine reviews 19, 798–827.
[20] Bates, A. S., Farrell, W. E., Bicknell, E. J., McNicol, A. M., Talbot, A. J.,
Broome, J. C., Perrett, C. W., Thakker, R. V., and Clayton, R. N. (1997) Al-
lelic deletion in pituitary adenomas reflects aggressive biological activity and has
potential value as a prognostic marker. The Journal of clinical endocrinology and
metabolism 82, 818–824.
[21] Zhang, X., Horwitz, G. A., Heaney, A. P., Nakashima, M., Prezant, T. R.,
Bronstein, M. D., and Melmed, S. (1999) Pituitary tumor transforming gene
(PTTG) expression in pituitary adenomas. The Journal of clinical endocrinology
and metabolism 84, 761–767.
[22] Saeger, W., Ludecke, D. K., Buchfelder, M., Fahlbusch, R., Quabbe, H.-J., and
Petersenn, S. (2007) Pathohistological classification of pituitary tumors: 10 years
of experience with the German Pituitary Tumor Registry. European journal of
endocrinology / European Federation of Endocrine Societies 156, 203–216.
[23] Buurman, H., and Saeger, W. (2006) Subclinical adenomas in postmortem pitu-
itaries: classification and correlations to clinical data. European journal of en-
docrinology / European Federation of Endocrine Societies 154, 753–758.
67
BIBLIOGRAPHY
[24] Kruse, A., Astrup, J., Gyldensted, C., and Cold, G. E. (1995) Hyperprolactinaemia
in patients with pituitary adenomas. The pituitary stalk compression syndrome.
British journal of neurosurgery 9, 453–457.
[25] Skinner, D. C. (2009) Rethinking the stalk effect: a new hypothesis explaining
suprasellar tumor-induced hyperprolactinemia. Medical hypotheses 72, 309–310.
[26] Greenman, Y., and Stern, N. (2009) Non-functioning pituitary adenomas. Best
practice & research 23, 625–638.
[27] Melmed, S. (2011) Pathogenesis of pituitary tumors. Nature reviews 7, 257–266.
[28] Abe, T., Tara, L. A., and Ludecke, D. K. (1999) Growth hormone-secreting pitu-
itary adenomas in childhood and adolescence: features and results of transnasal
surgery. Neurosurgery 45, 1–10.
[29] Nachtigall, L., Delgado, A., Swearingen, B., Lee, H., Zerikly, R., and Klibanski, A.
(2008) Changing patterns in diagnosis and therapy of acromegaly over two decades.
The Journal of clinical endocrinology and metabolism 93, 2035–2041.
[30] Dekkers, O. M., Biermasz, N. R., Pereira, A. M., Romijn, J. A., and Vanden-
broucke, J. P. (2008) Mortality in acromegaly: a metaanalysis. The Journal of
clinical endocrinology and metabolism 93, 61–67.
[31] Melmed, S. (2009) Acromegaly pathogenesis and treatment. The Journal of clinical
investigation 119, 3189–3202.
[32] Colao, A., Di Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R.,
Di Somma, C., Faggiano, A., Biondi, B., and Lombardi, G. (2003) Gender differ-
ences in the prevalence, clinical features and response to cabergoline in hyperpro-
lactinemia. European journal of endocrinology / European Federation of Endocrine
Societies 148, 325–331.
[33] Mindermann, T., and Wilson, C. B. (1994) Age-related and gender-related occur-
rence of pituitary adenomas. Clinical endocrinology 41, 359–364.
[34] Bertagna, X., Guignat, L., Groussin, L., and Bertherat, J. (2009) Cushing’s disease.
Best practice & research 23, 607–623.
[35] Kirk, L. F. J., Hash, R. B., Katner, H. P., and Jones, T. (2000) Cushing’s disease:
clinical manifestations and diagnostic evaluation. American family physician 62,
1119–27, 1133–4.
[36] Beck-Peccoz, P., Persani, L., Mannavola, D., and Campi, I. (2009) Pituitary tu-
mours: TSH-secreting adenomas. Best practice & research 23, 597–606.
68
BIBLIOGRAPHY
[37] Socin, H. V., Chanson, P., Delemer, B., Tabarin, A., Rohmer, V., Mockel, J.,
Stevenaert, A., and Beckers, A. (2003) The changing spectrum of TSH-secreting
pituitary adenomas: diagnosis and management in 43 patients. European journal
of endocrinology / European Federation of Endocrine Societies 148, 433–442.
[38] Brucker-Davis, F., Oldfield, E. H., Skarulis, M. C., Doppman, J. L., and Wein-
traub, B. D. (1999) Thyrotropin-secreting pituitary tumors: diagnostic criteria,
thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the
National Institutes of Health. The Journal of clinical endocrinology and metabolism
84, 476–486.
[39] Young, W. F. J., Scheithauer, B. W., Kovacs, K. T., Horvath, E., Davis, D. H.,
and Randall, R. V. (1996) Gonadotroph adenoma of the pituitary gland: a clini-
copathologic analysis of 100 cases. Mayo Clinic proceedings 71, 649–656.
[40] Cooper, O., Geller, J. L., and Melmed, S. (2008) Ovarian hyperstimulation syn-
drome caused by an FSH-secreting pituitary adenoma. Nature clinical practice 4,
234–238.
[41] Snyder, P. J. (1985) Gonadotroph cell adenomas of the pituitary. Endocrine reviews
6, 552–563.
[42] Yamada, S., Ohyama, K., Taguchi, M., Takeshita, A., Morita, K., Takano, K., and
Sano, T. (2007) A study of the correlation between morphological findings and
biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery
61, 580–4; discussion 584–5.
[43] Kwekkeboom, D. J., Jong, F. H. d., and Lamberts, S. W. (1989) Gonadotropin re-
lease by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and
in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-
releasing hormone, and bromocriptine. The Journal of clinical endocrinology and
metabolism 68, 1128–1135.
[44] Kaltsas, G., Nomikos, P., Kontogeorgos, G., Buchfelder, M., and Grossman, A.
(2005) Clinical review: Diagnosis and management of pituitary carcinomas. The
Journal of clinical endocrinology and metabolism 90, 3089–3099.
[45] Zada, G., Woodmansee, W. W., Ramkissoon, S., Amadio, J., Nose, V., and
Laws, E. R. J. (2011) Atypical pituitary adenomas: incidence, clinical charac-
teristics, and implications. Journal of neurosurgery 114, 336–344.
[46] Colao, A., Ochoa, A. S., Auriemma, R. S., Faggiano, A., Pivonello, R., and Lom-
bardi, G. (2010) Pituitary carcinomas. Frontiers of hormone research 38, 94–108.
[47] Arnold, P. M., Ratnasingam, D., O’Neil, M. F., and Johnson, P. L. (2012) Pituitary
carcinoma recurrent to the lumbar intradural extramedullary space: case report.
The journal of spinal cord medicine 35, 118–121.
69
BIBLIOGRAPHY
[48] Bode, H., Seiz, M., Lammert, A., Brockmann, M. A., Back, W., Hammes, H.-P.,
and Thome, C. (2010) SOM230 (pasireotide) and temozolomide achieve sustained
control of tumour progression and ACTH secretion in pituitary carcinoma with
widespread metastases. Experimental and clinical endocrinology & diabetes : offi-
cial journal, German Society of Endocrinology [and] German Diabetes Association
118, 760–763.
[49] Curto, L., Torre, M. L., Ferrau, F., Pitini, V., Altavilla, G., Granata, F., Longo, M.,
Hofland, L. J., Trimarchi, F., and Cannavo, S. (2010) Temozolomide-induced
shrinkage of a pituitary carcinoma causing Cushing’s disease–report of a case and
literature review. TheScientificWorldJournal 10, 2132–2138.
[50] Moshkin, O., Syro, L. V., Scheithauer, B. W., Ortiz, L. D., Fadul, C. E., Uribe, H.,
Gonzalez, R., Cusimano, M., Horvath, E., Rotondo, F., and Kovacs, K. (2011)
Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the
role of temozolomide therapy. Hormones (Athens, Greece) 10, 162–167.
[51] Hirohata, T. et al. (2013) DNA Mismatch Repair Protein (MSH6) Correlated With
the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temo-
zolomide: The National Cooperative Study by the Japan Society for Hypothalamic
and Pituitary Tumors. The Journal of clinical endocrinology and metabolism
[52] Annamalai, A. K., Dean, A. F., Kandasamy, N., Kovacs, K., Burton, H., Hal-
sall, D. J., Shaw, A. S., Antoun, N. M., Cheow, H. K., Kirollos, R. W.,
Pickard, J. D., Simpson, H. L., Jefferies, S. J., Burnet, N. G., and Gurnell, M.
(2011) Temozolomide responsiveness in aggressive corticotroph tumours: a case
report and review of the literature. Pituitary
[53] Raverot, G. et al. (2010) Temozolomide treatment in aggressive pituitary tumors
and pituitary carcinomas: a French multicenter experience. The Journal of clinical
endocrinology and metabolism 95, 4592–4599.
[54] Losa, M., Mazza, E., Terreni, M. R., McCormack, A., Gill, A. J., Motta, M.,
Cangi, M. G., Talarico, A., Mortini, P., and Reni, M. (2010) Salvage therapy
with Temozolomide in patients with aggressive or metastatic pituitary adenomas:
experience in six cases. European journal of endocrinology / European Federation
of Endocrine Societies
[55] Murakami, M., Mizutani, A., Asano, S., Katakami, H., Ozawa, Y., Yamazaki, K.,
Ishida, Y., Takano, K., Okinaga, H., and Matsuno, A. (2011) A mechanism
of acquiring temozolomide resistance during transformation of atypical prolacti-
noma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 68,
E1761–7; discussion E1767.
[56] Ilkhchoui, Y., Appelbaum, D. E., and Pu, Y. (2010) FDG-PET/CT findings of a
metastatic pituitary tumor. Cancer imaging : the official publication of the Inter-
national Cancer Imaging Society 10, 114–116.
70
BIBLIOGRAPHY
[57] Lee, W., Cheung, A. S., and Freilich, R. (2012) TSH-secreting pituitary carcinoma
with intrathecal drop metastases. Clinical endocrinology 76, 604–606.
[58] Dudziak, K., Honegger, J., Bornemann, A., Horger, M., and Mussig, K. (2011)
Pituitary carcinoma with malignant growth from first presentation and fulminant
clinical course–case report and review of the literature. The Journal of clinical
endocrinology and metabolism 96, 2665–2669.
[59] Thearle, M. S., Freda, P. U., Bruce, J. N., Isaacson, S. R., Lee, Y., and Fine, R. L.
(2011) Temozolomide (Temodar(R)) and capecitabine (Xeloda(R)) treatment of
an aggressive corticotroph pituitary tumor. Pituitary 14, 418–424.
[60] Morokuma, H., Ando, T., Hayashida, T., Horie, I., Inoshita, N., Murata, F.,
Ueki, I., Nakamura, K., Imaizumi, M., Usa, T., and Kawakami, A. (2012) A case
of nonfunctioning pituitary carcinoma that responded to temozolomide treatment.
Case reports in endocrinology 2012, 645914.
[61] Bush, Z. M., Longtine, J. A., Cunningham, T., Schiff, D., Jane, J. A. J.,
Vance, M. L., Thorner, M. O., Laws, E. R. J., and Lopes, M. B. (2010) Temo-
zolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Out-
come with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation
and Expression. The Journal of clinical endocrinology and metabolism
[62] Pernicone, P. J., Scheithauer, B. W., Sebo, T. J., Kovacs, K. T., Horvath, E.,
Young, W. F. J., Lloyd, R. V., Davis, D. H., Guthrie, B. L., and Schoene, W. C.
(1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79, 804–
812.
[63] Ragel, B., and Couldwell, W. (2004) Pituitary carcinoma: a review of the litera-
ture. Neurosurgical focus 16, E7.
[64] Buchfelder, M., and Schlaffer, S. (2009) Surgical treatment of pituitary tumours.
Best practice & research 23, 677–692.
[65] Buchfelder, M. (2005) Treatment of pituitary tumors: surgery. Endocrine 28, 67–
75.
[66] Ciric, I., Ragin, A., Baumgartner, C., and Pierce, D. (1997) Complications of
transsphenoidal surgery: results of a national survey, review of the literature, and
personal experience. Neurosurgery 40, 225–36; discussion 236–7.
[67] Couldwell, W. T. (2004) Transsphenoidal and transcranial surgery for pituitary
adenomas. Journal of neuro-oncology 69, 237–256.
[68] Sasaki, R., Murakami, M., Okamoto, Y., Kono, K., Yoden, E., Nakajima, T.,
Nabeshima, S., and Kuroda, Y. (2000) The efficacy of conventional radiation ther-
apy in the management of pituitary adenoma. International journal of radiation
oncology, biology, physics 47, 1337–1345.
71
BIBLIOGRAPHY
[69] Loeﬄer, J. S., and Shih, H. A. (2011) Radiation therapy in the management of pi-
tuitary adenomas. The Journal of clinical endocrinology and metabolism 96, 1992–
2003.
[70] Minniti, G., Gilbert, D. C., and Brada, M. (2009) Modern techniques for pituitary
radiotherapy. Reviews in endocrine & metabolic disorders 10, 135–144.
[71] Brada, M., Rajan, B., Traish, D., Ashley, S., Holmes-Sellors, P. J., Nussey, S., and
Uttley, D. (1993) The long-term efficacy of conservative surgery and radiotherapy
in the control of pituitary adenomas. Clinical endocrinology 38, 571–578.
[72] Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velke-
niers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., Mahler, C.,
Stevenaert, A., Verlooy, J., Raftopoulos, C., and Beckers, A. (1999) Cabergoline
in the treatment of hyperprolactinemia: a study in 455 patients. The Journal of
clinical endocrinology and metabolism 84, 2518–2522.
[73] Colao, A., and Savastano, S. (2011) Medical treatment of prolactinomas. Nature
reviews 7, 267–278.
[74] Abs, R., Verhelst, J., Maiter, D., van Acker, K., Nobels, F., Coolens, J. L.,
Mahler, C., and Beckers, A. (1998) Cabergoline in the treatment of acromegaly:
a study in 64 patients. The Journal of clinical endocrinology and metabolism 83,
374–378.
[75] Pivonello, R., Martino, M. C. d., Cappabianca, P., Leo, M. d., Faggiano, A., Lom-
bardi, G., Hofland, L. J., Lamberts, S. W. J., and Colao, A. (2009) The med-
ical treatment of Cushing’s disease: effectiveness of chronic treatment with the
dopamine agonist cabergoline in patients unsuccessfully treated by surgery. The
Journal of clinical endocrinology and metabolism 94, 223–230.
[76] Colao, A., Di Somma, C., Pivonello, R., Faggiano, A., Lombardi, G., and Savas-
tano, S. (2008) Medical therapy for clinically non-functioning pituitary adenomas.
Endocrine-related cancer 15, 905–915.
[77] Gillam, M. P., Molitch, M. E., Lombardi, G., and Colao, A. (2006) Advances in
the treatment of prolactinomas. Endocrine reviews 27, 485–534.
[78] Chanson, P., Salenave, S., Kamenicky, P., Cazabat, L., and Young, J. (2009) Pi-
tuitary tumours: acromegaly. Best practice & research 23, 555–574.
[79] Mannavola, D., Persani, L., Vannucchi, G., Zanardelli, M., Fugazzola, L.,
Verga, U., Facchetti, M., and Beck-Peccoz, P. (2005) Different responses to chronic
somatostatin analogues in patients with central hyperthyroidism. Clinical en-
docrinology 62, 176–181.
72
BIBLIOGRAPHY
[80] Bronstein, M. D., Knoepfelmacher, M., Liberman, B., Marino, R. J., Ger-
mek, O. A., and Schally, A. V. (1987) Absence of suppressive effect of somatostatin
on prolactin levels in patients with hyperprolactinemia. Hormone and metabolic
research 19, 271–274.
[81] Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M.,
Schoenherr, U., Mills, D., Salgado, L. R., and Biller, B. M. K. (2012) A 12-month
phase 3 study of pasireotide in Cushing’s disease. The New England journal of
medicine 366, 914–924.
[82] Hofland, L. J., and Lamberts, S. W. J. (2004) Somatostatin receptors in pituitary
function, diagnosis and therapy. Frontiers of hormone research 32, 235–252.
[83] Ceccato, F., Scaroni, C., and Boscaro, M. (2015) Clinical use of pasireotide for
Cushing’s disease in adults. Therapeutics and clinical risk management 11, 425–
434.
[84] Sherlock, M., Woods, C., and Sheppard, M. (2011) Medical therapy in acromegaly.
Nature reviews 7, 291–300.
[85] Kopchick, J. J., Parkinson, C., Stevens, E. C., and Trainer, P. J. (2002) Growth
hormone receptor antagonists: discovery, development, and use in patients with
acromegaly. Endocrine reviews 23, 623–646.
[86] Tritos, N., Biller, B., and Swearingen, B. (2011) Management of Cushing disease.
Nature reviews 7, 279–289.
[87] Bertagna, X., Pivonello, R., Fleseriu, M., Zhang, Y., Robinson, P., Taylor, A.,
Watson, C. E., Maldonado, M., Hamrahian, A. H., Boscaro, M., and Biller, B.
M. K. (2014) LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary
cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-
concept study. The Journal of clinical endocrinology and metabolism 99, 1375–
1383.
[88] Denny, B. J., Wheelhouse, R. T., Stevens, M. F., Tsang, L. L., and Slack, J. A.
(1994) NMR and molecular modeling investigation of the mechanism of activation
of the antitumor drug temozolomide and its interaction with DNA. Biochemistry
33, 9045–9051.
[89] Newlands, E. S., Stevens, M. F., Wedge, S. R., Wheelhouse, R. T., and Brock, C.
(1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical
development and clinical trials. Cancer treatment reviews 23, 35–61.
[90] Newlands, E. S., Blackledge, G. R., Slack, J. A., Rustin, G. J., Smith, D. B., Stu-
art, N. S., Quarterman, C. P., Hoffman, R., Stevens, M. F., and Brampton, M. H.
(1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
British journal of cancer 65, 287–291.
73
BIBLIOGRAPHY
[91] Beale, P., Judson, I., Moore, S., Statkevich, P., Marco, A., Cutler, D. L., Reiden-
berg, P., and Brada, M. (1999) Effect of gastric pH on the relative oral bioavail-
ability and pharmacokinetics of temozolomide. Cancer chemotherapy and pharma-
cology 44, 389–394.
[92] Brada, M., Judson, I., Beale, P., Moore, S., Reidenberg, P., Statkevich, P.,
Dugan, M., Batra, V., and Cutler, D. (1999) Phase I dose-escalation and phar-
macokinetic study of temozolomide (SCH 52365) for refractory or relapsing malig-
nancies. British journal of cancer 81, 1022–1030.
[93] Rosso, L., Brock, C. S., Gallo, J. M., Saleem, A., Price, P. M., Turkheimer, F. E.,
and Aboagye, E. O. (2009) A new model for prediction of drug distribution in
tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients.
Cancer research 69, 120–127.
[94] Baker, S. D., Wirth, M., Statkevich, P., Reidenberg, P., Alton, K., Sartorius, S. E.,
Dugan, M., Cutler, D., Batra, V., Grochow, L. B., Donehower, R. C., and Rowin-
sky, E. K. (1999) Absorption, metabolism, and excretion of 14C-temozolomide
following oral administration to patients with advanced cancer. Clinical cancer re-
search : an official journal of the American Association for Cancer Research 5,
309–317.
[95] Stevens, M. F., Hickman, J. A., Langdon, S. P., Chubb, D., Vickers, L., Stone, R.,
Baig, G., Goddard, C., Gibson, N. W., and Slack, J. A. (1987) Antitumor activ-
ity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo5,1-d-1,2,3,5-
tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as
an alternative to dacarbazine. Cancer research 47, 5846–5852.
[96] Lee, S. M., Thatcher, N., Crowther, D., and Margison, G. P. (1994) Inactivation
of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear
cells by temozolomide. British journal of cancer 69, 452–456.
[97] Ortiz, L. D., Syro, L. V., Scheithauer, B. W., Rotondo, F., Uribe, H., Fadul, C. E.,
Horvath, E., and Kovacs, K. (2012) Temozolomide in aggressive pituitary adeno-
mas and carcinomas. Clinics (Sao Paulo, Brazil) 67 Suppl 1, 119–123.
[98] Garcia, M., Clopes, A., Bruna, J., Martinez, M., Fort, E., and Gil, M. (2009)
Critical appraisal of temozolomide formulations in the treatment of primary brain
tumors: patient considerations. Cancer management and research 1, 137–150.
[99] Shah, D., Kelly, J., Zhang, Y., Dande, P., Martinez, J., Ortiz, G., Fronza, G.,
Tran, H., Soto, A. M., Marky, L., and Gold, B. (2001) Evidence in Escherichia coli
that N3-methyladenine lesions induced by a minor groove binding methyl sulfonate
ester can be processed by both base and nucleotide excision repair. Biochemistry
40, 1796–1803.
74
BIBLIOGRAPHY
[100] Engelward, B. P., Dreslin, A., Christensen, J., Huszar, D., Kurahara, C., and
Samson, L. (1996) Repair-deficient 3-methyladenine DNA glycosylase homozygous
mutant mouse cells have increased sensitivity to alkylation-induced chromosome
damage and cell killing. The EMBO journal 15, 945–952.
[101] Kaina, B., Margison, G. P., and Christmann, M. (2010) Targeting O (6)-
methylguanine-DNA methyltransferase with specific inhibitors as a strategy in
cancer therapy. Cellular and molecular life sciences : CMLS
[102] Swenson, D. H., Harbach, P. R., and Trzos, R. J. (1980) The relationship between
alkylation of specific DNA bases and induction of sister chromatid exchange. Car-
cinogenesis 1, 931–936.
[103] Gaffney, B. L., and Jones, R. A. (1989) Thermodynamic comparison of the base
pairs formed by the carcinogenic lesion O6-methylguanine with reference both to
Watson-Crick pairs and to mismatched pairs. Biochemistry 28, 5881–5889.
[104] Quiros, S., Roos, W. P., and Kaina, B. (2010) Processing of O6-methylguanine into
DNA double-strand breaks requires two rounds of replication whereas apoptosis is
also induced in subsequent cell cycles. Cell cycle (Georgetown, Tex 9, 168–178.
[105] Karran, P., and Bignami, M. (1992) Self-destruction and tolerance in resistance of
mammalian cells to alkylation damage. Nucleic acids research 20, 2933–2940.
[106] Ceccotti, S., Aquilina, G., Macpherson, P., Yamada, M., Karran, P., and Big-
nami, M. (1996) Processing of O6-methylguanine by mismatch correction in human
cell extracts. Current biology : CB 6, 1528–1531.
[107] Kaina, B., Ziouta, A., Ochs, K., and Coquerelle, T. (1997) Chromosomal instabil-
ity, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-,
Mex+ and methylation-tolerant mismatch repair compromised cells: facts and
models. Mutation research 381, 227–241.
[108] Bignami, M., O’Driscoll, M., Aquilina, G., and Karran, P. (2000) Unmasking a
killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mu-
tation research 462, 71–82.
[109] Gerson, S. L., Trey, J. E., Miller, K., and Berger, N. A. (1986) Comparison of
O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in
human, rat and mouse tissues. Carcinogenesis 7, 745–749.
[110] Pegg, A. E. (1990) Mammalian O6-alkylguanine-DNA alkyltransferase: regulation
and importance in response to alkylating carcinogenic and therapeutic agents.
Cancer research 50, 6119–6129.
75
BIBLIOGRAPHY
[111] Srivenugopal, K. S., Yuan, X. H., Friedman, H. S., and Ali-Osman, F.
(1996) Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyl-
transferase in human and murine tumor cells following inactivation with O6-
benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 35, 1328–
1334.
[112] Wang, Y., Li, J., Tohti, M., Hu, Y., Wang, S., Li, W., Lu, Z., and Ma, C. (2014)
The expression profile of Dopamine D2 receptor, MGMT and VEGF in different
histological subtypes of pituitary adenomas: a study of 197 cases and indications
for the medical therapy. Journal of experimental & clinical cancer research : CR
33, 56.
[113] McCormack, A. I., McDonald, K. L., Gill, A. J., Clark, S. J., Burt, M. G., Camp-
bell, K. A., Braund, W. J., Little, N. S., Cook, R. J., Grossman, A. B., Robin-
son, B. G., and Clifton-Bligh, R. J. (2009) Low O6-methylguanine-DNA methyl-
transferase (MGMT) expression and response to temozolomide in aggressive pitu-
itary tumours. Clinical endocrinology 71, 226–233.
[114] Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F.,
Vanaclocha, V., Baylin, S. B., and Herman, J. G. (2000) Inactivation of the DNA-
repair gene MGMT and the clinical response of gliomas to alkylating agents. The
New England journal of medicine 343, 1350–1354.
[115] Whitelaw, B. C., Dworakowska, D., Thomas, N. W., Barazi, S., Riordan-Eva, P.,
King, A. P., Hampton, T., Landau, D. B., Lipscomb, D., Buchanan, C. R.,
Gilbert, J. A., and Aylwin, S. J. B. (2012) Temozolomide in the management
of dopamine agonist-resistant prolactinomas. Clinical endocrinology 76, 877–886.
[116] Greenhill, C. (2011) Pituitary tumors: MGMT expression patterns explored. Na-
ture Reviews Endocrinology 7, 249.
[117] Salehi, F., Scheithauer, B. W., Kros, J. M., Lau, Q., Fealey, M., Erickson, D.,
Kovacs, K., Horvath, E., and Lloyd, R. V. (2011) MGMT promoter methylation
and immunoexpression in aggressive pituitary adenomas and carcinomas. Journal
of neuro-oncology 104, 647–657.
[118] van, N. K. A., van, d. B. J., van, d. M. W., Ameziane, N., Wedekind, L. E.,
Steenbergen, R. D., Leenstra, S., Lafleur, M. V., Slotman, B. J., Stalpers, L. J.,
and Sminia, P. (2010) Absence of the MGMT protein as well as methylation of
the MGMT promoter predict the sensitivity for temozolomide. British journal of
cancer 103, 29–35.
[119] Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P.,
and Gilbert, M. R. (2008) Correlation of O6-methylguanine methyltransferase
(MGMT) promoter methylation with clinical outcomes in glioblastoma and clini-
cal strategies to modulate MGMT activity. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 26, 4189–4199.
76
BIBLIOGRAPHY
[120] Balmaceda, C., Peereboom, D., Pannullo, S., Cheung, Y. K. K., Fisher, P. G.,
Alavi, J., Sisti, M., Chen, J., and Fine, R. L. (2008) Multi-institutional phase
II study of temozolomide administered twice daily in the treatment of recurrent
high-grade gliomas. Cancer 112, 1139–1146.
[121] Hunter, C. et al. (2006) A hypermutation phenotype and somatic MSH6 muta-
tions in recurrent human malignant gliomas after alkylator chemotherapy. Cancer
research 66, 3987–3991.
[122] Cahill, D. P., Levine, K. K., Betensky, R. A., Codd, P. J., Romany, C. A.,
Reavie, L. B., Batchelor, T. T., Futreal, P. A., Stratton, M. R., Curry, W. T.,
Iafrate, A. J., and Louis, D. N. (2007) Loss of the mismatch repair protein MSH6
in human glioblastomas is associated with tumor progression during temozolomide
treatment. Clinical cancer research : an official journal of the American Associa-
tion for Cancer Research 13, 2038–2045.
[123] Yip, S., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., and
Louis, D. N. (2009) MSH6 mutations arise in glioblastomas during temozolomide
therapy and mediate temozolomide resistance. Clinical cancer research : an official
journal of the American Association for Cancer Research 15, 4622–4629.
[124] Karran, P., Offman, J., and Bignami, M. (2003) Human mismatch repair, drug-
induced DNA damage, and secondary cancer. Biochimie 85, 1149–1160.
[125] Matsuno, A. et al. (2014) Molecular status of pituitary carcinoma and atypical
adenoma that contributes the effectiveness of temozolomide. Medical molecular
morphology 47, 1–7.
[126] Nguyen, S. A., Stechishin, O. D. M., Luchman, H. A., Lun, X. Q., Senger, D. L.,
Robbins, S. M., Cairncross, J. G., and Weiss, S. (2014) Novel MSH6 mutations
in treatment-naive glioblastoma and anaplastic oligodendroglioma contribute to
temozolomide resistance independently of MGMT promoter methylation. Clini-
cal cancer research : an official journal of the American Association for Cancer
Research 20, 4894–4903.
[127] Stevens, M. F., Hickman, J. A., Stone, R., Gibson, N. W., Baig, G. U., Lunt, E.,
and Newton, C. G. (1984) Antitumor imidazotetrazines. 1. Synthesis and chem-
istry of 8-carbamoyl-3-(2-chloroethyl)imidazo-1,2,3,5-tetrazin-4(3 H)-one , a novel
broad-spectrum antitumor agent. Journal of medicinal chemistry 27, 196–201.
[128] Middleton, M. R. et al. (2000) Randomized phase III study of temozolomide ver-
sus dacarbazine in the treatment of patients with advanced metastatic malignant
melanoma. Journal of clinical oncology : official journal of the American Society
of Clinical Oncology 18, 158–166.
[129] Paul, M. J., Summers, Y., Calvert, A. H., Rustin, G., Brampton, M. H.,
Thatcher, N., and Middleton, M. R. (2002) Effect of temozolomide on central
77
BIBLIOGRAPHY
nervous system relapse in patients with advanced melanoma. Melanoma research
12, 175–178.
[130] Dummer, R., Hauschild, A., and Pentheroudakis, G. (2009) Cutaneous malignant
melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-
up. Annals of oncology : official journal of the European Society for Medical On-
cology / ESMO 20 Suppl 4, 129–131.
[131] Yung, W. K. et al. (1999) Multicenter phase II trial of temozolomide in pa-
tients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse.
Temodal Brain Tumor Group. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 17, 2762–2771.
[132] Yung, W. K. et al. (2000) A phase II study of temozolomide vs. procarbazine in
patients with glioblastoma multiforme at first relapse. British journal of cancer
83, 588–593.
[133] van den Bent, M. J., Taphoorn, M. J. B., Brandes, A. A., Menten, J., Stupp, R.,
Frenay, M., Chinot, O., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., All-
geier, A., and Gorlia, T. (2003) Phase II study of first-line chemotherapy with
temozolomide in recurrent oligodendroglial tumors: the European Organization
for Research and Treatment of Cancer Brain Tumor Group Study 26971. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology
21, 2525–2528.
[134] Wick, W., Steinbach, J. P., Kuker, W. M., Dichgans, J., Bamberg, M., and
Weller, M. (2004) One week on/one week off: a novel active regimen of temo-
zolomide for recurrent glioblastoma. Neurology 62, 2113–2115.
[135] Stupp, R. et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. The New England journal of medicine 352, 987–996.
[136] U. S. National Institutes of health, Database of clinical studies conducted around
the world. http://www.clinicaltrials.gov/.
[137] European Medicines Agency, Temozolomide European public assessment report.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/
medicines/000229/human_med_001085.jsp\&mid=WC0b01ac058001d124.
[138] U. S. Food and Drug Administration, Temodar Label. http://www.fda.gov/.
[139] Rabik, C. A., Njoku, M. C., and Dolan, M. E. (2006) Inactivation of O6-
alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer
treatment reviews 32, 261–276.
[140] Broniscer, A., Gururangan, S., MacDonald, T. J., Goldman, S., Packer, R. J.,
Stewart, C. F., Wallace, D., Danks, M. K., Friedman, H. S., Poussaint, T. Y.,
78
BIBLIOGRAPHY
Kun, L. E., Boyett, J. M., and Gajjar, A. (2007) Phase I trial of single-dose temo-
zolomide and continuous administration of o6-benzylguanine in children with brain
tumors: a pediatric brain tumor consortium report. Clinical cancer research : an
official journal of the American Association for Cancer Research 13, 6712–6718.
[141] Quinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J.,
Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H.,
McLendon, R. E., Herndon, J. E. n., Walker, A., and Friedman, H. S. (2009)
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent,
temozolomide-resistant malignant glioma. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 27, 1262–1267.
[142] Tentori, L., and Graziani, G. (2009) Recent approaches to improve the antitumor
efficacy of temozolomide. Current medicinal chemistry 16, 245–257.
[143] Kefford, R. F., Thomas, N. P. B., Corrie, P. G., Palmer, C., Abdi, E., Kotasek, D.,
Beith, J., Ranson, M., Mortimer, P., Watson, A. J., Margison, G. P., and Mid-
dleton, M. R. (2009) A phase I study of extended dosing with lomeguatrib with
temozolomide in patients with advanced melanoma. British journal of cancer 100,
1245–1249.
[144] Chalmers, A. J. (2009) The potential role and application of PARP inhibitors in
cancer treatment. British medical bulletin 89, 23–40.
[145] Palma, J. P. et al. (2009) ABT-888 confers broad in vivo activity in combination
with temozolomide in diverse tumors. Clinical cancer research : an official journal
of the American Association for Cancer Research 15, 7277–7290.
[146] Strosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D.-T.,
Helm, J., and Kvols, L. (2011) First-line chemotherapy with capecitabine and
temozolomide in patients with metastatic pancreatic endocrine carcinomas. Can-
cer 117, 268–275.
[147] Gulati, A. P., Krantz, B., Moss, R. A., Moyal, W. N., Tsushima, D. A.,
Mowatt, K. B., Schreibman, S., and Fine, R. L. (2013) Treatment of multiple
endocrine neoplasia 1/2 tumors: case report and review of the literature. Oncology
84, 127–134.
[148] Chen, M., Osman, I., and Orlow, S. J. (2009) Antifolate activity of pyrimethamine
enhances temozolomide-induced cytotoxicity in melanoma cells. Molecular cancer
research : MCR 7, 703–712.
[149] Dai, C. et al. (2013) Inhibition of PI3K/AKT/mTOR Pathway Enhances
Temozolomide-Induced Cytotoxicity in Pituitary Adenoma Cell Lines in Vitro
and Xenografted Pituitary Adenoma in Female Nude Mice. Endocrinology 154,
1247–1259.
79
BIBLIOGRAPHY
[150] Zhu, Y., Shahinian H.„ Hakimian B.„ Bonert V.„ Lim S.„ and Heaney A., (2004)
Temodar: novel treatment for pituitary carcinoma. US Endocrine Society 43–45.
[151] Kovacs, K., Horvath, E., Syro, L. V., Uribe, H., Penagos, L. C., Ortiz, L. D., and
Fadul, C. E. (2007) Temozolomide therapy in a man with an aggressive prolactin-
secreting pituitary neoplasm: Morphological findings. Human pathology 38, 185–
189.
[152] Hagen, C., Schroeder, H. D., Hansen, S., and Andersen, M. (2009) Temozolomide
treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to
conventional therapy. European journal of endocrinology / European Federation of
Endocrine Societies 161, 631–637.
[153] Fadul, C. E., Kominsky, A. L., Meyer, L. P., Kingman, L. S., Kinlaw, W. B.,
Rhodes, C. H., Eskey, C. J., and Simmons, N. E. (2006) Long-term response of
pituitary carcinoma to temozolomide. Report of two cases. Journal of neurosurgery
105, 621–626.
[154] Mohammed, S., Kovacs, K., Mason, W., Smyth, H., and Cusimano, M. D. (2009)
Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64,
E773–4; discussion E774.
[155] Dixit, S., Baker, L., Walmsley, V., and Hingorani, M. (2012) Temozolomide-related
idiosyncratic and other uncommon toxicities: a systematic review. Anti-cancer
drugs 23, 1099–1106.
[156] Niewald, M., Berdel, C., Fleckenstein, J., Licht, N., Ketter, R., and Rube, C.
(2011) Toxicity after radiochemotherapy for glioblastoma using temozolomide–a
retrospective evaluation. Radiation oncology (London, England) 6, 141.
[157] Jen, J. F., Cutler, D. L., Pai, S. M., Batra, V. K., Affrime, M. B., Zambas, D. N.,
Heft, S., and Hajian, G. (2000) Population pharmacokinetics of temozolomide in
cancer patients. Pharmaceutical research 17, 1284–1289.
[158] Evans, A. C., Nelson, M. B., and Dhall, G. (2015) Pregnancy in a Patient With
a Malignant Brain Tumor Taking Temozolomide: Case Report and Review of the
Literature. Journal of pediatric oncology nursing : official journal of the Associa-
tion of Pediatric Oncology Nurses
[159] Schwarzberg, A. B., Stover, E. H., Sengupta, T., Michelini, A., Vincitore, M.,
Baden, L. R., and Kulke, M. H. (2007) Selective lymphopenia and opportunis-
tic infections in neuroendocrine tumor patients receiving temozolomide. Cancer
investigation 25, 249–255.
[160] Su, Y. B., Sohn, S., Krown, S. E., Livingston, P. O., Wolchok, J. D., Quinn, C.,
Williams, L., Foster, T., Sepkowitz, K. A., and Chapman, P. B. (2004) Selective
CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity
80
BIBLIOGRAPHY
with therapeutic implications. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 22, 610–616.
[161] Vos, F. Y. d., Gijtenbeek, J. M., Bleeker-Rovers, C. P., and van Herpen, C. M.
(2013) Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treat-
ment for high-grade gliomas. Critical reviews in oncology/hematology 85, 373–382.
[162] Neuwelt, A. J., Nguyen, T. M., Fu, R., Bubalo, J., Tyson, R. M., Lacy, C., Gahra-
manov, S., Nasseri, M., Barnes, P. D., and Neuwelt, E. A. (2014) Incidence of
Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies with-
out prophylaxis. CNS oncology 3, 267–273.
[163] Faje, A. T., Nachtigall, L., Wexler, D., Miller, K. K., Klibanski, A., and
Makimura, H. (2013) Central diabetes insipidus: a previously unreported side
effect of temozolomide. The Journal of clinical endocrinology and metabolism 98,
3926–3931.
[164] Momota, H., Narita, Y., Miyakita, Y., and Shibui, S. (2013) Secondary hemato-
logical malignancies associated with temozolomide in patients with glioma. Neuro-
oncology 15, 1445–1450.
[165] Deluche, E., Leobon, S., Touraine, F., and Clavere, P. (2014) Two cases of cu-
taneous drug eruption associated with temozolomide therapy for glioblastoma.
Current oncology (Toronto, Ont 21, e779–81.
[166] Yildirim, A. E., Divanlioglu, D., Nacar, O. A., Dursun, E., Sahinoglu, M., Unal, T.,
and Belen, A. D. (2013) Incidence, hormonal distribution and postoperative follow
up of atypical pituitary adenomas. Turkish neurosurgery 23, 226–231.
[167] Sheehan, J., Rainey, J., Nguyen, J., Grimsdale, R., and Han, S. (2011)
Temozolomide-induced inhibition of pituitary adenoma cells. Journal of neuro-
surgery 114, 354–358.
[168] Ma, S., Liu, X., Yao, Y., Cai, F., Dai, C., Bao, X., Feng, M., Wei, J., Zhang, B.,
Li, G., Ma, W., and Wang, R. (2011) Effect of temozolomide on cell viability in
gonadotroph adenoma cell lines. Oncology reports 26, 543–550.
[169] Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J., and van, B. C. (2006)
Clonogenic assay of cells in vitro. Nature protocols 1, 2315–2319.
[170] Niyazi, M., Niyazi, I., and Belka, C. (2007) Counting colonies of clonogenic assays
by using densitometric software. Radiation oncology (London, England) 2, 4.
[171] Ijichi, A., Sakuma, S., and Tofilon, P. J. (1995) Hypoxia-induced vascular endothe-
lial growth factor expression in normal rat astrocyte cultures. Glia 14, 87–93.
[172] Kovacs, K., Scheithauer, B. W., Horvath, E., and Lloyd, R. V. (1996) The World
Health Organization classification of adenohypophysial neoplasms. A proposed
five-tier scheme. Cancer 78, 502–510.
81
BIBLIOGRAPHY
[173] Kim, J., Kim, J.-S., Ko, K., Kong, D.-S., Kang, C.-M., Kim, M., Son, M., Song, H.,
Shin, H.-J., Lee, D.-S., Eoh, W., and Nam, D.-H. (2006) Metronomic treatment
of temozolomide inhibits tumor cell growth through reduction of angiogenesis and
augmentation of apoptosis in orthotopic models of gliomas. Oncology reports 16,
33–39.
[174] Syro, L. V., Uribe, H., Penagos, L. C., Ortiz, L. D., Fadul, C. E., Horvath, E.,
and Kovacs, K. (2006) Antitumour effects of temozolomide in a man with a large,
invasive prolactin-producing pituitary neoplasm. Clinical endocrinology 65, 552–
553.
[175] Ersen, A., Syro, L. V., Penagos, L., Uribe, H., Scheithauer, B. W., Ortiz, L. D.,
Rotondo, F., Horvath, E., and Kovacs, K. (2012) Non-uniform response to temo-
zolomide therapy in a pituitary gonadotroph adenoma. The Canadian journal of
neurological sciences 39, 683–685.
[176] Dhodapkar, M., Rubin, J., Reid, J. M., Burch, P. A., Pitot, H. C., Buckner, J. C.,
Ames, M. M., and Suman, V. J. (1997) Phase I trial of temozolomide (NSC 362856)
in patients with advanced cancer. Clinical cancer research : an official journal of
the American Association for Cancer Research 3, 1093–1100.
[177] Hammond, L. A., Eckardt, J. R., Baker, S. D., Eckhardt, S. G., Dugan, M., For-
ral, K., Reidenberg, P., Statkevich, P., Weiss, G. R., Rinaldi, D. A., Hoff, D. D. v.,
and Rowinsky, E. K. (1999) Phase I and pharmacokinetic study of temozolomide on
a daily-for-5-days schedule in patients with advanced solid malignancies. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology
17, 2604–2613.
[178] Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F., Decosterd, L. A.,
and Stupp, R. (2004) Plasma and cerebrospinal fluid population pharmacokinetics
of temozolomide in malignant glioma patients. Clinical cancer research : an official
journal of the American Association for Cancer Research 10, 3728–3736.
[179] Blumenthal, R. D., and Goldenberg, D. M. (2007) Methods and goals for the use of
in vitro and in vivo chemosensitivity testing. Molecular biotechnology 35, 185–197.
[180] Hueng, D.-Y., Ma, H.-I., Sytwu, H.-K., and Liu, M.-Y. (2011) Temozolomide and
pituitary adenoma. Journal of neurosurgery 114, 1820: author reply 1820–1.
[181] Ongena, K., Das, C., Smith, J. L., Gil, S., and Johnston, G. (2010) Determining
cell number during cell culture using the Scepter cell counter. Journal of visualized
experiments : JoVE
[182] Jiang, W. G. et al. (2015) Tissue invasion and metastasis: Molecular, biological
and clinical perspectives. Seminars in cancer biology
[183] Hoffman, R. M. (1991) In vitro sensitivity assays in cancer: a review, analysis, and
prognosis. Journal of clinical laboratory analysis 5, 133–143.
82
BIBLIOGRAPHY
[184] Wang, G. L., and Semenza, G. L. (1993) General involvement of hypoxia-inducible
factor 1 in transcriptional response to hypoxia. Proceedings of the National
Academy of Sciences of the United States of America 90, 4304–4308.
[185] Huang, L. E., Arany, Z., Livingston, D. M., and Bunn, H. F. (1996) Activation
of hypoxia-inducible transcription factor depends primarily upon redox-sensitive
stabilization of its alpha subunit. The Journal of biological chemistry 271, 32253–
32259.
[186] Hardee, M. E., and Formenti, S. C. (2012) Combining stereotactic radiosurgery
and systemic therapy for brain metastases: a potential role for temozolomide.
Frontiers in oncology 2, 99.
[187] Bengtsson, D., Schroder, H. D., Andersen, M., Maiter, D., Berinder, K., Feldt Ras-
mussen, U., Rasmussen, A. K., Johannsson, G., Hoybye, C., van der Lely, A. J.,
Petersson, M., Ragnarsson, O., and Burman, P. (2015) Long-Term Outcome and
MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas
and Pituitary Carcinomas Given Treatment With Temozolomide. The Journal of
clinical endocrinology and metabolism 100, 1689–1698.
[188] Jugenburg, M., Kovacs, K., Stefaneanu, L., and Scheithauer, B. W. (1995) Vas-
culature in Nontumorous Hypophyses, Pituitary Adenomas, and Carcinomas: A
Quantitative Morphologic Study. Endocrine pathology 6, 115–124.
[189] Vidal, S., Kovacs, K., Horvath, E., Scheithauer, B., Kuroki, T., and Lloyd, R.
(2001) Microvessel density in pituitary adenomas and carcinomas. Virchows Archiv
438, 595–602.
[190] Onofri, C., Theodoropoulou, M., Losa, M., Uhl, E., Lange, M., Arzt, E.,
Stalla, G. K., and Renner, U. (2006) Localization of vascular endothelial growth
factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a
non-endothelial function of VEGF in pituitary tumours. The Journal of endocrinol-
ogy 191, 249–261.
[191] Lloyd, R. V., Scheithauer, B. W., Kuroki, T., Vidal, S., Kovacs, K., and Ste-
faneanu, L. (1999) Vascular endothelial growth factor (VEGF) expression in hu-
man pituitary adenomas and carcinomas. Endocrine pathology 10, 229–235.
[192] Ghadimi, B. M., and Schlag, P. M. (1998) Tumor metastasis. Molecular principles
and therapeutic options. Der Chirurg; Zeitschrift fur alle Gebiete der operativen
Medizen 69, 1315–1322.
[193] Sanchez-Ortiga, R., Sanchez-Tejada, L., Moreno-Perez, O., Riesgo, P., Niveiro, M.,
and Pico Alfonso, A. M. (2013) Over-expression of vascular endothelial growth
factor in pituitary adenomas is associated with extrasellar growth and recurrence.
Pituitary 16, 370–377.
83
BIBLIOGRAPHY
[194] Luque, G. M., Perez-Millan, M. I., Ornstein, A. M., Cristina, C., and Becu-
Villalobos, D. (2011) Inhibitory effects of antivascular endothelial growth factor
strategies in experimental dopamine-resistant prolactinomas. The Journal of phar-
macology and experimental therapeutics 337, 766–774.
[195] Wang, G. L., Jiang, B. H., Rue, E. A., and Semenza, G. L. (1995) Hypoxia-
inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular
O2 tension. Proceedings of the National Academy of Sciences of the United States
of America 92, 5510–5514.
[196] Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Strat-
ford, I. J., Hankinson, O., Pugh, C. W., and Ratcliffe, P. J. (1997) Hypoxia-
inducible factor-1 modulates gene expression in solid tumors and influences both
angiogenesis and tumor growth. Proceedings of the National Academy of Sciences
of the United States of America 94, 8104–8109.
[197] Kim, K., Yoshida, D., and Teramoto, A. (2005) Expression of hypoxia-inducible
factor 1alpha and vascular endothelial growth factor in pituitary adenomas. En-
docrine pathology 16, 115–121.
[198] Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q.,
Dillehay, L. E., Madan, A., Semenza, G. L., and Bedi, A. (2000) Regulation of
tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Genes & development 14, 34–44.
[199] Zhou, Q., Guo, P., Wang, X., Nuthalapati, S., and Gallo, J. M. (2007) Preclinical
pharmacokinetic and pharmacodynamic evaluation of metronomic and conven-
tional temozolomide dosing regimens. The Journal of pharmacology and experi-
mental therapeutics 321, 265–275.
[200] Kurzen, H., Schmitt, S., Naher, H., and Mohler, T. (2003) Inhibition of angiogen-
esis by non-toxic doses of temozolomide. Anti-cancer drugs 14, 515–522.
[201] Cerovac, V., Monteserin-Garcia, J., Rubinfeld, H., Buchfelder, M., Losa, M., Flo-
rio, T., Paez-Pereda, M., Stalla, G. K., and Theodoropoulou, M. (2010) The so-
matostatin analogue octreotide confers sensitivity to rapamycin treatment on pi-
tuitary tumor cells. Cancer research 70, 666–674.
[202] Gorshtein, A., Rubinfeld, H., Kendler, E., Theodoropoulou, M., Cerovac, V.,
Stalla, G. K., Cohen, Z. R., Hadani, M., and Shimon, I. (2009) Mammalian tar-
get of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-
proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocrine-
related cancer 16, 1017–1027.
[203] Zatelli, M. C., Minoia, M., Filieri, C., Tagliati, F., Buratto, M., Ambrosio, M. R.,
Lapparelli, M., Scanarini, M., and Degli Uberti, E. C. (2010) Effect of everolimus
84
BIBLIOGRAPHY
on cell viability in nonfunctioning pituitary adenomas. The Journal of clinical
endocrinology and metabolism 95, 968–976.
[204] Jouanneau, E., Wierinckx, A., Ducray, F., Favrel, V., Borson-Chazot, F., Honno-
rat, J., Trouillas, J., and Raverot, G. (2012) New targeted therapies in pituitary
carcinoma resistant to temozolomide. Pituitary 15, 37–43.
[205] Bobola, M. S., Kolstoe, D. D., Blank, A., and Silber, J. R. (2010) Minimally
cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma
cells regardless of MGMT expression. Molecular cancer therapeutics 9, 1208–1218.
[206] Kil, W. J., Cerna, D., Burgan, W. E., Beam, K., Carter, D., Steeg, P. S.,
Tofilon, P. J., and Camphausen, K. (2008) In vitro and in vivo radiosensitization
induced by the DNA methylating agent temozolomide. Clinical cancer research :
an official journal of the American Association for Cancer Research 14, 931–938.
[207] Brada, M., Ashley, S., Dowe, A., Gonsalves, A., Huchet, A., Pesce, G., Reni, M.,
Saran, F., Wharram, B., Wilkins, M., and Wilkins, P. (2005) Neoadjuvant phase II
multicentre study of new agents in patients with malignant glioma after minimal
surgery. Report of a cohort of 187 patients treated with temozolomide. Annals of
oncology : official journal of the European Society for Medical Oncology / ESMO
16, 942–949.
[208] Friedman, H. S. et al. (1998) DNA mismatch repair and O6-alkylguanine-DNA
alkyltransferase analysis and response to Temodal in newly diagnosed malignant
glioma. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 16, 3851–3857.
[209] Brock, C. S., Newlands, E. S., Wedge, S. R., Bower, M., Evans, H., Colquhoun, I.,
Roddie, M., Glaser, M., Brampton, M. H., and Rustin, G. J. (1998) Phase I trial
of temozolomide using an extended continuous oral schedule. Cancer research 58,
4363–4367.
[210] Tolcher, A. W., Gerson, S. L., Denis, L., Geyer, C., Hammond, L. A., Patnaik, A.,
Goetz, A. D., Schwartz, G., Edwards, T., Reyderman, L., Statkevich, P., Cut-
ler, D. L., and Rowinsky, E. K. (2003) Marked inactivation of O6-alkylguanine-
DNA alkyltransferase activity with protracted temozolomide schedules. British
journal of cancer 88, 1004–1011.
[211] Gilbert, M. R. et al. (2013) Dose-dense temozolomide for newly diagnosed glioblas-
toma: a randomized phase III clinical trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 31, 4085–4091.
[212] Matsuyama, J. (2012) Ki-67 expression for predicting progression of postopera-
tive residual pituitary adenomas: correlations with clinical variables. Neurologia
medico-chirurgica 52, 563–569.
85
BIBLIOGRAPHY
[213] Di Ieva, A., Rotondo, F., Syro, L. V., Cusimano, M. D., and Kovacs, K. (2014)
Aggressive pituitary adenomas–diagnosis and emerging treatments. Nature reviews
10, 423–435.
[214] Brem, S., Tyler, B., Li, K., Pradilla, G., Legnani, F., Caplan, J., and Brem, H.
(2007) Local delivery of temozolomide by biodegradable polymers is superior to
oral administration in a rodent glioma model. Cancer chemotherapy and pharma-
cology 60, 643–650.
[215] Wait, S. D., Prabhu, R. S., Burri, S. H., Atkins, T. G., and Asher, A. L. (2015)
Polymeric drug delivery for the treatment of glioblastoma. Neuro-oncology 17 Suppl
2, ii9–ii23.
[216] Masi, B. C., Tyler, B. M., Bow, H., Wicks, R. T., Xue, Y., Brem, H., Langer, R.,
and Cima, M. J. (2012) Intracranial MEMS based temozolomide delivery in a 9L
rat gliosarcoma model. Biomaterials 33, 5768–5775.
[217] Lim, S., Shahinian, H., Maya, M. M., Yong, W., and Heaney, A. P. (2006) Temo-
zolomide: a novel treatment for pituitary carcinoma. The lancet oncology 7, 518–
520.
[218] Neff, L. M., Weil, M., Cole, A., Hedges, T. R., Shucart, W., Lawrence, D.,
Zhu, J. J., Tischler, A. S., and Lechan, R. M. (2007) Temozolomide in the treat-
ment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10,
81–86.
[219] Kovacs, K., Scheithauer, B. W., Lombardero, M., McLendon, R. E., Syro, L. V.,
Uribe, H., Ortiz, L. D., and Penagos, L. C. (2008) MGMT immunoexpression
predicts responsiveness of pituitary tumors to temozolomide therapy. Acta neu-
ropathologica 115, 261–262.
[220] Guzel, A., Tatli, M., Senturk, S., Guzel, E., Cayli, S. R., and Sav, A. (2008)
Pituitary carcinoma presenting with multiple metastases: case report. Journal of
child neurology 23, 1467–1471.
[221] Takeshita, A., Inoshita, N., Taguchi, M., Okuda, C., Fukuhara, N., Oyama, K.,
Ohashi, K., Sano, T., Takeuchi, Y., and Yamada, S. (2009) High incidence of low
O(6)-methylguanine DNA methyltransferase expression in invasive macroadeno-
mas of Cushing’s disease. European journal of endocrinology / European Federation
of Endocrine Societies 161, 553–559.
[222] Moyes, V. J., Alusi, G., Sabin, H. I., Evanson, J., Berney, D. M., Kovacs, K.,
Monson, J. P., Plowman, P. N., and Drake, W. M. (2009) Treatment of Nelson’s
syndrome with temozolomide. European journal of endocrinology / European Fed-
eration of Endocrine Societies 160, 115–119.
86
BIBLIOGRAPHY
[223] Byrne, S., Karapetis, C., and Vrodos, N. (2009) A novel use of temozolomide in
a patient with malignant prolactinoma. Journal of clinical neuroscience : official
journal of the Neurosurgical Society of Australasia 16, 1694–1696.
[224] Syro, L. V., Scheithauer, B. W., Ortiz, L. D., Fadul, C. E., Horvath, E., Ro-
tondo, F., and Kovacs, K. (2009) Effect of temozolomide in a patient with recur-
ring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens, Greece) 8,
303–306.
[225] Scheithauer, B. W., Horvath, E., Abel, T. W., Robital, Y., Park, S.-H., Os-
amura, R. Y., Deal, C., Lloyd, R. V., and Kovacs, K. (2012) Pituitary blastoma:
a unique embryonal tumor. Pituitary 15, 365–373.
[226] Dillard, T. H., Gultekin, S. H., Delashaw, J. B. J., Yedinak, C. G., Neuwelt, E. A.,
and Fleseriu, M. (2011) Temozolomide for corticotroph pituitary adenomas refrac-
tory to standard therapy. Pituitary 14, 80–91.
[227] Morin, E., Berthelet, F., Weisnagel, J., Bidlingmaier, M., and Serri, O. (2012) Fail-
ure of temozolomide and conventional doses of pegvisomant to attain biochemical
control in a severe case of acromegaly. Pituitary 15, 97–100.
[228] Rotondo, F., Cusimano, M., Scheithauer, B. W., Coire, C., Horvath, E., and Ko-
vacs, K. (2012) Atypical, invasive, recurring Crooke cell adenoma of the pituitary.
Hormones (Athens, Greece) 11, 94–100.
[229] Philippon, M., Morange, I., Barrie, M., Barlier, A., Taieb, D., Dufour, H., Conte-
Devolx, B., Brue, T., and Castinetti, F. (2012) Long-term control of a MEN1
prolactin secreting pituitary carcinoma after temozolomide treatment. Annales
d’endocrinologie
[230] Phillips, J., East, H. E., French, S. E., Melcescu, E., Hamilton, R. D.,
Nicholas, W. C., Fratkin, J. F., Parent, A. D., Luzardo, G., and Koch, C. A.
(2012) What causes a prolactinoma to be aggressive or to become a pituitary
carcinoma? Hormones (Athens, Greece) 11, 477–482.
[231] Batisse, M., Raverot, G., Maqdasy, S., Durando, X., Sturm, N., Montoriol, P.-
F., Kemeny, J. L., Chazal, J., Trouillas, J., and Tauveron, I. (2013) Aggressive
silent GH pituitary tumor resistant to multiple treatments, including temozolo-
mide. Cancer investigation 31, 190–196.
[232] Zemmoura, I., Wierinckx, A., Vasiljevic, A., Jan, M., Trouillas, J., and Francois, P.
(2013) Aggressive and malignant prolactin pituitary tumors: pathological diagnosis
and patient management. Pituitary 16, 515–522.
[233] Cornell, R. F., Kelly, D. F., Bordo, G., Carroll, T. B., Duong, H. T., Kim, J., Taka-
sumi, Y., Thomas, J. P., Wong, Y. L., and Findling, J. W. (2013) Chemotherapy-
induced regression of an adrenocorticotropin-secreting pituitary carcinoma accom-
87
BIBLIOGRAPHY
panied by secondary adrenal insufficiency. Case reports in endocrinology 2013,
675298.
[234] Asimakopoulou, A., Tzanela, M., Koletti, A., Kontogeorgos, G., and Tsagarakis, S.
(2014) Long-term remission in an aggressive Crooke cell adenoma of the pituitary,
18 months after discontinuation of treatment with temozolomide. Clinical case
reports 2, 1–3.
[235] Zhong, C., Yin, S., Zhou, P., and Jiang, S. (2014) Pituitary atypical adenoma
or carcinoma sensitive to temozolomide combined with radiation therapy: a case
report of early identification and management. Turkish neurosurgery 24, 963–966.
[236] Strowd, R., Salvatori, R., and Laterra, J. (2015) Temozolomide retreatment in
a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic
response. Journal of oncology pharmacy practice : official publication of the Inter-
national Society of Oncology Pharmacy Practitioners
[237] Ghazi, A. A., Rotondo, F., Kovacs, K., Amirbaigloo, A., Syro, L. V., Fathalla, H.,
Di Ieva, A., and Cusimano, M. D. (2015) Treatment of Invasive Silent Somatotroph
Pituitary Adenoma with Temozolomide. Report of a Case and Review of the Lit-
erature. Endocrine pathology
88
Acknowledgement
The completion of this thesis would not have been possible without the invaluable sup-
port of several people:
First of all I’d like to express my heartfelt thanks to my supervisor Dr. Ulrich Renner
for his continuous guidance throughout the entire time. I appreciate his readiness to
share his expertise and to quickly solve problems.
I am thankful to Prof. Stalla for his friendly guidance and advice and for giving me the
opportunity to work on this interesting project.
I am grateful to all my colleages in the lab, Shan Bing, José Luis Monteserin Garcia,
Barbara Wölfel, Monika Makrutzki, Marily Theodoropoulou and Marta Labeur. My
special thanks go to Anne Schmidt, who always kept an encouraging warm smile on her
face, though she had to face a lot of difficulties.
I want to direct my sincere thanks to Johanna Stalla for her priceless help and patient
explanations of radioimmunoassays.
Vesna Cerovac deserves my deepest thank for her help and patience in teaching me the
methods used in this thesis.
I am very much indebted to my parents, who supported and encouraged me throughout
my whole study period and who longed to see this achievement come true.
Last, I’d like to thank Christoph for his imperturbable belief in me. His advice, critical
judgement and continuous encouragement were invaluable for me.
89
[Curriculum vitae not available in electronic version]
[Curriculum vitae not available in electronic version]
A. Application of Temozolomide in the
Treatment of Pituitary Adenomas
92
Table A.1. Usage of temozolomide in the treatment of pituitary tumors
MGMT immunohistochemistry: <10%=Low, 11-50%=Intermediate, >51%=High
Age = Age at diagnosis. Status on April 15, 2015.
Tumor Age Gender Response
MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Prolactin
carcinoma
61 male Yes Yes Yes No data No data
Zhu et al.
(2004) [150]
Prolactinoma 46 male Yes Yes PRL fell from 1838 μg/l to 30
μg/l
Low No data
Syro et al.
(2006)
[174, 151]
Prolactin
carcinoma
26 male Only
initially
Only initially Yes No data No data
Fadul et al.
(2006) [153]
Gonadotroph
carcinoma
38 male Yes Yes Not applicable No data No data
Fadul et al.
(2006) [153]
Prolactin
carcinoma
65 male Yes Yes PRL fell from 73 000IU/l to
6,1 IU/l
No data No data
Lim et al
(2006) [217]
Prolactinoma 52 female Yes Yes PRL fell from 7,000 ng/ml to
150-260ng/ml
No data No data
Neff et al.
(2007) [218]
Adreno-
corticotroph
carcinoma
23 male No No No data High No data
Kovacs et al.
(2008)
[219, 50]
Non-
functioning
pituitary
carcinoma
9 female No No No No data No data
Guzel et al.
(2008) [220]
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MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Somato-
tropinoma
48 male No No No High No data
McCormack
et al. (2009)
[113]
Prolactin
carcinoma
42 male Yes Yes PRL fell from 504 602 mlU/l
to 90 863 mlU/l
Low No data
McCormack
et al. (2009)
[113]
Adreno-
corticotroph
carcinoma
46 female Yes Yes ACTH fell from 15 000 pg/ml
to 20,8 pg/ml
Low No data
Takeshita et.
al. (2009)
[221]
Adreno-
corticotroph
carcinoma
64 female Yes Yes ACTH fell from 2472 pmol/l
to 389 pmol/l
Low No data
Moyes et al.
(2009) [222]
NFPA 28 female No data Yes No data No data No data
Mohammed et
al. (2009)
[154]
Adreno-
corticotroph
carcinoma
60 male Yes Only initially ACTH fell from 140 pmol/l to
21 pmol/l
High No data
Mohammed et
al. (2009)
[154]
Adreno-
corticotroph
adenoma
43 female Yes Yes Yes Low No data
Mohammed et
al. (2009)
[154]
NFPA 20 male Yes Yes Not applicable Low No data
Hagen et al.
(2009) [152]
Prolactinoma 60 male Yes Yes PRL fell from 650 to 18 μg/l Low No data
Hagen et al.
(2009) [152]
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Tumor Age Gender Response
MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Prolactin
carcinoma
48 female Yes Yes PRL fell from 738μg/l to 14
μg/l
Low No data
Hagen et al.
(2009) [152]
Prolactinoma 64 male Yes Yes PRL fell from 504 000 mlU/l
to 24 000mlU/l
No data No data
Byrne et al.
(2009) [223]
NFPA 52 male No Yes No data High No data
Syro et al.
(2009) [224]
Adreno-
corticotroph
adenoma
42 male Yes Yes No data Low No data
Curto et al.
(2010) [49]
Adreno-
corticotroph
carcinoma
No
data
No data Yes Yes Yes No data No data
Bode et al.
(2010) [48]
NFPA
No
data
No data Stable Stable Not applicable High
unmethyl-
ated
Bush et al.
(2010) [61]
Adreno-
corticotroph
adenoma
No
data
No data Yes Yes ACTH fell from 221pg/ml to
18pg/ml
Low
unmethyl-
ated
Bush et al.
(2010) [61]
Gonado-
tropinoma
No
data
No data Stable Stable Not applicable
Inter-
mediate
unmethyl-
ated
Bush et al.
(2010) [61]
NFPA
No
data
No data Stable Stable Not applicable High
unmethyl-
ated
Bush et al.
(2010) [61]
Prolactinoma
No
data
No data Yes Yes PRL fell from 5702 ng/ml to
121ng/ml
Low
unmethyl-
ated
Bush et al.
(2010) [61]
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Tumor Age Gender Response
MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Carcinoma
No
data
No data No data Stable No data High No data
Bush et al.
(2010) [61]
Carcinoma
No
data
No data No data No No data Low
unmethyl-
ated
Bush et al.
(2010) [61]
Adreno-
corticotroph
adenoma
57 male No No No data No data No data
Losa et al.
(2010) [54]
Adreno-
corticotroph
carcinoma
46 male Yes Yes ACTH fell from 237pg/ml to
10pg/ml
Low No data
Losa et al.
(2010) [54]
Adreno-
corticotroph
adenoma
40 female Stable Only initially ACTH fell from 6144 pg/ml to
3580 pg/ml, then rose to 6750
pg/ml
High
unmethyl-
ated
Losa et al.
(2010) [54]
Adreno-
corticotroph
adenoma
28 female No No No High
unmethyl-
ated
Losa et al.
(2010) [54]
Prolactinoma 55 male Stable Stable PRL fell from 2800 ng/ml to
1232 ng/ml, then rose again
Low
unmethyl-
ated
Losa et al.
(2010) [54]
Prolactinoma 53 female Yes Yes PRL fell from 1845 ng/ml to 8
ng/ml
No data
unmethyl-
ated
Losa et al.
(2010) [54]
Prolactin
carcinoma
32 male No data Yes PRL normalization No data No data
Raverot et al.
(2010) [53]
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Tumor Age Gender Response
MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Prolactin
carcinoma
52 male No No No
Inter-
mediate
unmethyl-
ated
Raverot et al.
(2010) [53]
Prolactinoma 54 male No No No Low 8,5%
Raverot et al.
(2010) [53]
Prolactin
carcinoma
30 female No No No High No data
Raverot et al.
(2010) [53]
Adreno-
corticotroph
carcinoma
31 male No data No No
Inter-
mediate
2,6%
Raverot et al.
(2010) [53]
Adreno-
corticotroph
adenoma
49 male No data No No Low No data
Raverot et al.
(2010) [53]
Adreno-
corticotroph
carcinoma
38 male Yes Yes ACTH fell from 135 to 64 ng/l
Inter-
mediate
No data
Raverot et al.
(2010) [53]
Adreno-
corticotroph
adenoma
42 female Yes Yes ACTH fell from 114 to 47 ng/l Low 9,8%
Raverot et al.
(2010) [53]
Prolactin
carcinoma
54 female Only
initially
Only initially PRL fell from 2355ng/ml to
42,2ng/ml, then rose to 714,4
ng/ml
Low No data
Murakami et
al. (2011) [55]
Adreno-
corticotroph
carcinoma
50 male Only
initially
Only initially ACTH fell from 1,874 pg/ml
to 309pg/ml
No data No data
Thearle et al.
(2011) [59]
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MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Pituitary
blastoma
1 female Ony
initially
Only initially No data High No data
Scheithauer et
al. (2011)
[225]
Adreno-
corticotroph
carcinoma
44 male No No Not applicable High No data
Ortiz et al.
(2011) [97]
Adreno-
corticotroph
carcinoma
65 male Yes Yes ACTH fell from 5685ng/l to
2318 ng/l
Low No data
Annamalai et
al. (2011) [52]
Adreno-
corticotroph
adenoma
58 male Yes Yes ACTH fell from 67.3 pmol/l to
15.2 pmol/l
No data
unmethyl-
ated
Dillard et al.
(2011) [226]
Adreno-
corticotroph
carcinoma
48 female Only
initially
No data No data No data No data
Arnold et al.
(2012) [47]
Somato-
tropinoma
22 male No No No No data No data
Morin et al.
(2012) [227]
Prolactinoma 13 male Yes Yes PRL fell from 49 000 to
3515mlU/l
Low No data
Whitelaw et
al. (2012)
[115]
Prolactinoma 34 male Yes Yes PRL fell from 90 000 to
3222mlU/l
Low
unmethyl-
ated
Whitelaw et
al. (2012)
[115]
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Tumor Age Gender Response
MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Prolactinoma 32 male Yes Yes PRL fell from 24 000 to
4540mlU/l
Low No data
Whitelaw et
al. (2012)
[115]
Adreno-
corticotroph
adenoma
49 female Yes Yes No data Low No data
Rotondo et al.
(2012) [228]
Carcinoma 58 male Yes Yes Not applicable Low No data
Morokuma et
al. (2012) [60]
Prolactin
carcinoma
No
data
male Yes No data Yes No data No data
Phillipon et
al. (2012)
[229]
Gonado-
tropinoma
50 male Stable Stable No data Intermediate No data
Ersen et al.
(2012) [175]
Prolactin
carcinoma
25 male No No No No data No data
Phillips et al.
(2012) [230]
Prolactin
carcinoma
54 male Yes Yes PRL return to normal No data No data
Gulati et al.
(2013) [147]
Somato-
tropinoma
47 male No No data No data High
unmethyl-
ated
Batisse et al.
(2013) [231]
Prolactinoma 54 male No No No No data No data
Zemmoura et
al. (2013)
[232]
Adreno-
corticotroph
carcinoma
40 male No No No No data No data
Cornell er al.
(2013) [233]99
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MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
NFPA 59 male Yes No data Not applicable High No data
Hirohata et
al. (2013) [51]
Adreno-
corticotroph
adenoma
42 female Yes No data No data Low No data
Hirohata et
al. (2013) [51]
Prolactinoma 60 female Only
initially
No data No data Low No data
Hirohata et
al. (2013) [51]
NFPA 23 male Stable No data Not applicable High No data
Hirohata et
al. (2013) [51]
Adreno-
corticotroph
adenoma
53 female Yes No data No data High No data
Hirohata et
al. (2013) [51]
Prolactinoma 60 female Yes No data No data High No data
Hirohata et
al. (2013) [51]
Adreno-
corticotroph
adenoma
57 male Stable No data No data High No data
Hirohata et
al. (2013) [51]
NFPA 73 female Yes No data Not applicable Low No data
Hirohata et
al. (2013) [51]
Prolactinoma 60 male No No data No data Low No data
Hirohata et
al. (2013) [51]
NFPA 61 female No No data Not applicable High No data
Hirohata et
al. (2013) [51]
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MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Prolactinoma 66 female Yes No data No data Low No data
Hirohata et
al. (2013) [51]
Prolactinoma 49 female No No data No data Low No data
Hirohata et
al. (2013) [51]
Adreno-
corticotroph
adenoma
45 female No No data No data High No data
Hirohata et
al. (2013) [51]
Adreno-
corticotroph
adenoma
55 female Yes Yes ACTH fell from 1854pmol/l to
21,1pmol/l
No data No data
Asimakopoulou
et al. (2013)
[234]
NFPA 30 female Yes Yes Not applicable No data No data
Zhong et al.
(2014) [235]
Prolactinoma 59 female Yes Yes PRL fell from 3902 to
28,8ng/ml
No data No data
Strowd et al.
(2015) [236]
NFPA 39 male No No Not applicable Low No data
Ghazi et el.
(2015 [237]
NFPA 67 female No No Not applicable No data No data
Ceccato et al
(2015) [83]
Gonado-
tropinoma
39 female No No No No data Low
Ceccato et al
(2015) [83]
NFPA 40 male No Yes Not applicable No data Low
Ceccato et al
(2015) [83]
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MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Adreno-
corticotroph
adenoma
32 male Yes Yes Yes No data Low
Ceccato et al
(2015) [83]
NFPA 47 male Stable Stable Not applicable No data Low
Ceccato et al
(2015) [83]
Somato-
tropinoma
31 female Yes Yes 66% decrease in GH-levels Intermediate No data
Bengtsson et
al. (2015)
[187]
Prolactinoma 33 male Yes Yes No data Low No data
Bengtsson et
al. (2015)
[187]
Prolactinoma 22 male Only
initially
Only initially No data High No data
Bengtsson et
al. (2015)
[187]
Prolactinoma 34 male Stable Stable 73% decrease in PRL levels Intermediate No data
Bengtsson et
al. (2015)
[187]
Prolactinoma 45 male No No No High No data
Bengtsson et
al. (2015)
[187]
Prolactinoma 55 male Yes Yes 73% decrease in PRL Low No data
Bengtsson et
al. (2015)
[187]
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MGMT
IHC
MGMT
Pro-
moter
Author
Clinical Radiological Biochemical
Prolactinoma 23 male No No No data High No data
Bengtsson et
al. (2015)
[187]
NFPA 45 male Yes Yes Not applicable High No data
Bengtsson et
al. (2015)
[187]
NFPA 52 female No No Not applicable High No data
Bengtsson et
al. (2015)
[187]
NFPA 59 male No No Not applicable High No data
Bengtsson et
al. (2015)
[187]
NFPA 57 male No No Not applicable High No data
Bengtsson et
al. (2015)
[187]
Adreno-
corticotroph
carcinoma
51 male Only
initially
Only initially 88% decrease in ACTH levels
for 6 months
Intermediate No data
Bengtsson et
al. (2015)
[187]
Adreno-
corticotroph
carcinoma
62 male No No No data High No data
Bengtsson et
al. (2015)
[187]
Adreno-
corticotroph
carcinoma
70 male Only
initially
Only initially 98% decrease of urinary free
cortisol
Low No data
Bengtsson et
al. (2015)
[187]
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Somatotrop
carcinoma
46 male No No No data High No data
Bengtsson et
al. (2015)
[187]
Somatotrop
carcinoma
40 female Yes Yes Normalisation of IGF-1 levels Low No data
Bengtsson et
al. (2015)
[187]
Prolactin
carcinoma
32 female No No No data Intermediate No data
Bengtsson et
al. (2015)
[187]
Prolactin
carcinoma
59 female Yes Yes 80% decrease in PRL levels No data No data
Bengtsson et
al. (2015)
[187]
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